WO2017139264A1 - Dna-guided gene editing and regulation - Google Patents
Dna-guided gene editing and regulation Download PDFInfo
- Publication number
- WO2017139264A1 WO2017139264A1 PCT/US2017/016827 US2017016827W WO2017139264A1 WO 2017139264 A1 WO2017139264 A1 WO 2017139264A1 US 2017016827 W US2017016827 W US 2017016827W WO 2017139264 A1 WO2017139264 A1 WO 2017139264A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- acid sequence
- target nucleic
- cell
- guide rna
- Prior art date
Links
- 230000033228 biological regulation Effects 0.000 title abstract description 13
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 389
- 229920001850 Nucleic acid sequence Polymers 0.000 claims abstract description 367
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 179
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 179
- 101700080605 NUC1 Proteins 0.000 claims abstract description 143
- 101700006494 nucA Proteins 0.000 claims abstract description 143
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 78
- 230000000295 complement Effects 0.000 claims abstract description 75
- 102000004190 Enzymes Human genes 0.000 claims abstract description 43
- 108090000790 Enzymes Proteins 0.000 claims abstract description 43
- 210000004027 cells Anatomy 0.000 claims description 209
- 108020005004 Guide RNA Proteins 0.000 claims description 142
- 229920002391 Guide RNA Polymers 0.000 claims description 142
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 132
- 108010082319 CRISPR-Associated Protein 9 Proteins 0.000 claims description 88
- 230000002103 transcriptional Effects 0.000 claims description 86
- 108020004707 nucleic acids Proteins 0.000 claims description 82
- 101710036216 ATEG_03556 Proteins 0.000 claims description 77
- 101710003000 ORF1/ORF2 Proteins 0.000 claims description 77
- 101700030467 Pol Proteins 0.000 claims description 77
- 101710004466 rgy Proteins 0.000 claims description 77
- 101710030364 rgy1 Proteins 0.000 claims description 77
- 101710030359 rgy2 Proteins 0.000 claims description 77
- 230000014509 gene expression Effects 0.000 claims description 58
- 229920000033 CRISPR Polymers 0.000 claims description 50
- 230000000051 modifying Effects 0.000 claims description 16
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 15
- 210000004962 mammalian cells Anatomy 0.000 claims description 13
- 108091006090 transcriptional activators Proteins 0.000 claims description 10
- 238000002744 homologous recombination Methods 0.000 claims description 6
- 108091006091 transcriptional repressors Proteins 0.000 claims description 6
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 156
- 230000004913 activation Effects 0.000 description 38
- 230000000694 effects Effects 0.000 description 35
- 229940088598 Enzyme Drugs 0.000 description 25
- 108091006088 gene-regulatory proteins Proteins 0.000 description 19
- 102000034448 gene-regulatory proteins Human genes 0.000 description 19
- 108060000497 piwi Proteins 0.000 description 19
- 210000000130 stem cell Anatomy 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 230000001627 detrimental Effects 0.000 description 13
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 11
- 238000001638 lipofection Methods 0.000 description 11
- 230000001105 regulatory Effects 0.000 description 11
- 108700000006 regulatory domains Proteins 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 108020004682 Single-Stranded DNA Proteins 0.000 description 10
- 241000192560 Synechococcus sp. Species 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 241000589499 Thermus thermophilus Species 0.000 description 9
- 230000002068 genetic Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000006011 modification reaction Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 230000000754 repressing Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 241000193996 Streptococcus pyogenes Species 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000001580 bacterial Effects 0.000 description 7
- 230000001404 mediated Effects 0.000 description 7
- 101700034118 myca Proteins 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 230000003612 virological Effects 0.000 description 7
- 108010088141 Argonaute Proteins Proteins 0.000 description 6
- 102000008682 Argonaute Proteins Human genes 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 229920000195 Bacterial small RNA Polymers 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 102000031025 DNA-Binding Proteins Human genes 0.000 description 6
- 108091000102 DNA-Binding Proteins Proteins 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 241001226557 Lyngbya confervoides Species 0.000 description 6
- 108009000261 Non-homologous end joining Proteins 0.000 description 6
- 101710026246 POU5F1 Proteins 0.000 description 6
- 102100019163 POU5F1 Human genes 0.000 description 6
- 241000205156 Pyrococcus furiosus Species 0.000 description 6
- 230000025458 RNA interference Effects 0.000 description 6
- 241001464991 Stanieria cyanosphaera Species 0.000 description 6
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 230000002708 enhancing Effects 0.000 description 6
- 230000001747 exhibiting Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000002987 rna-interference Effects 0.000 description 6
- 229940118764 FRANCISELLA TULARENSIS Drugs 0.000 description 5
- 241000589602 Francisella tularensis Species 0.000 description 5
- 101700022675 HBG Proteins 0.000 description 5
- 108020004999 Messenger RNA Proteins 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229920002106 messenger RNA Polymers 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000001743 silencing Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 238000010453 CRISPR/Cas method Methods 0.000 description 4
- SCKHCCSZFPSHGR-UHFFFAOYSA-N Cyanophos Chemical compound COP(=S)(OC)OC1=CC=C(C#N)C=C1 SCKHCCSZFPSHGR-UHFFFAOYSA-N 0.000 description 4
- 241000159506 Cyanothece Species 0.000 description 4
- 102100003272 GDF11 Human genes 0.000 description 4
- 101700065866 GDF11 Proteins 0.000 description 4
- 101700073128 HBG1 Proteins 0.000 description 4
- 102100004900 HBG1 Human genes 0.000 description 4
- 230000004570 RNA-binding Effects 0.000 description 4
- 101700006931 SOX2 Proteins 0.000 description 4
- 102100018829 SOX2 Human genes 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 241000194020 Streptococcus thermophilus Species 0.000 description 4
- 241001453296 Synechococcus elongatus Species 0.000 description 4
- 241001313706 Thermosynechococcus Species 0.000 description 4
- 241000589596 Thermus Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000010355 genome engineering Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 229920000023 polynucleotide Polymers 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- 241000203069 Archaea Species 0.000 description 3
- 229920005681 CRISPR RNA Polymers 0.000 description 3
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000531185 Ferroglobus placidus Species 0.000 description 3
- 101700048573 KLF4 Proteins 0.000 description 3
- 102100006525 KLF4 Human genes 0.000 description 3
- 210000004080 Milk Anatomy 0.000 description 3
- 241000588653 Neisseria Species 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 241000194019 Streptococcus mutans Species 0.000 description 3
- 230000003044 adaptive Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000000977 initiatory Effects 0.000 description 3
- 230000002452 interceptive Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000009906 meningitis Diseases 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 description 3
- 108060002324 polC Proteins 0.000 description 3
- 238000003153 stable transfection Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 241000432074 Adeno-associated virus Species 0.000 description 2
- 241000470051 Aromatoleum aromaticum Species 0.000 description 2
- 229940015062 Campylobacter jejuni Drugs 0.000 description 2
- 241000589875 Campylobacter jejuni Species 0.000 description 2
- 108010035563 Chloramphenicol O-Acetyltransferase Proteins 0.000 description 2
- 210000003483 Chromatin Anatomy 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 241000193155 Clostridium botulinum Species 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241001267419 Eubacterium sp. Species 0.000 description 2
- 241000423296 Gluconacetobacter diazotrophicus PA1 5 Species 0.000 description 2
- 108010070675 Glutathione Transferase family Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102100020039 HPGDS Human genes 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 210000000987 Immune System Anatomy 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 101710029649 MDV043 Proteins 0.000 description 2
- 241001486996 Methanocaldococcus Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000984652 Natrinema pellirubrum Species 0.000 description 2
- 108060007644 RAD50 Proteins 0.000 description 2
- 101700054624 RF1 Proteins 0.000 description 2
- 241000191043 Rhodobacter sphaeroides Species 0.000 description 2
- 102000003661 Ribonuclease III Human genes 0.000 description 2
- 108010057163 Ribonuclease III Proteins 0.000 description 2
- 101710043164 Segment-4 Proteins 0.000 description 2
- 229920000978 Start codon Polymers 0.000 description 2
- 229940031008 Streptococcus mutans Drugs 0.000 description 2
- 241000901742 Thermogladius calderae Species 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 101700038759 VP1 Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 102000004965 antibodies Human genes 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 108091005941 blue fluorescent protein Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 101700053531 chxR Proteins 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 108091005944 cyan fluorescent protein Proteins 0.000 description 2
- 230000004059 degradation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002538 fungal Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037240 fusion proteins Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 101700005460 hemA Proteins 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000010741 protein sumoylation Effects 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000000576 supplementary Effects 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 102000003995 transcription factors Human genes 0.000 description 2
- 108090000464 transcription factors Proteins 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091005946 yellow fluorescent protein Proteins 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 101700033661 ACTB Proteins 0.000 description 1
- 102100011550 ACTB Human genes 0.000 description 1
- 101710032514 ACTI Proteins 0.000 description 1
- 101700052657 ASCL Proteins 0.000 description 1
- 241001041760 Acidothermus cellulolyticus 11B Species 0.000 description 1
- 241000417230 Actinobacillus succinogenes 130Z Species 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N Actinospectacin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 241000778935 Akkermansia muciniphila ATCC BAA-835 Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000589941 Azospirillum Species 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 241000257169 Bacillus cereus ATCC 10987 Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241000186020 Bifidobacterium dentium Species 0.000 description 1
- 241001209261 Bifidobacterium longum DJO10A Species 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 241000589173 Bradyrhizobium Species 0.000 description 1
- 241001453247 Campylobacter jejuni subsp. doylei Species 0.000 description 1
- 241000941427 Campylobacter lari RM2100 Species 0.000 description 1
- 241001034636 Capnocytophaga ochracea DSM 7271 Species 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241001509423 Clostridium botulinum B Species 0.000 description 1
- 241001509504 Clostridium botulinum F Species 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241001487058 Corynebacterium efficiens YS-314 Species 0.000 description 1
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 1
- 241000671338 Corynebacterium glutamicum R Species 0.000 description 1
- 241001525611 Corynebacterium kroppenstedtii DSM 44385 Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000133 DNA Helicases Proteins 0.000 description 1
- 102000003844 DNA Helicases Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241001082278 Desulfovibrio salexigens DSM 2638 Species 0.000 description 1
- 241000688137 Diaphorobacter Species 0.000 description 1
- 241000933091 Dinoroseobacter shibae DFL 12 = DSM 16493 Species 0.000 description 1
- 241001338691 Elusimicrobium minutum Species 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 229920001272 Exogenous DNA Polymers 0.000 description 1
- 229920000665 Exon Polymers 0.000 description 1
- 241000608038 Fibrobacter succinogenes subsp. succinogenes S85 Species 0.000 description 1
- 241000359186 Finegoldia magna ATCC 29328 Species 0.000 description 1
- 241000382842 Flavobacterium psychrophilum Species 0.000 description 1
- 102100011343 GLB1 Human genes 0.000 description 1
- 102100004985 GUSB Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100019126 HBB Human genes 0.000 description 1
- 101700075536 HBG2 Proteins 0.000 description 1
- 102100004899 HBG2 Human genes 0.000 description 1
- 241000546751 Halopiger xanaduensis Species 0.000 description 1
- 241001453258 Helicobacter hepaticus Species 0.000 description 1
- 108091005902 Hemoglobin subunit beta Proteins 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 102000008157 Histone Demethylases Human genes 0.000 description 1
- 108010074870 Histone Demethylases Proteins 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 102000003964 Histone deacetylases Human genes 0.000 description 1
- 108090000353 Histone deacetylases Proteins 0.000 description 1
- 208000006572 Human Influenza Diseases 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- 108010015268 Integration Host Factors Proteins 0.000 description 1
- 241000037075 Intestinibacter bartlettii Species 0.000 description 1
- 229920002459 Intron Polymers 0.000 description 1
- 241001596092 Kribbella flavida DSM 17836 Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 229940017800 Lactobacillus casei Drugs 0.000 description 1
- 240000004403 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 229940059406 Lactobacillus rhamnosus GG Drugs 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 241001427851 Lactobacillus salivarius UCC118 Species 0.000 description 1
- 241001193656 Legionella pneumophila str. Paris Species 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 101710011991 MYCBP2 Proteins 0.000 description 1
- 241001378931 Methanococcus maripaludis C7 Species 0.000 description 1
- 210000003470 Mitochondria Anatomy 0.000 description 1
- 229920000460 Mitochondrial DNA Polymers 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 241000825684 Mycobacterium abscessus ATCC 19977 Species 0.000 description 1
- 241000204022 Mycoplasma gallisepticum Species 0.000 description 1
- 241000107400 Mycoplasma mobile 163K Species 0.000 description 1
- 241001135743 Mycoplasma penetrans Species 0.000 description 1
- 241000051161 Mycoplasma synoviae 53 Species 0.000 description 1
- 101700064338 NFCP Proteins 0.000 description 1
- 229920002957 Naked DNA Polymers 0.000 description 1
- 241001417618 Natronobacterium gregoryi SP2 Species 0.000 description 1
- 241001648684 Nitrobacter hamburgensis X14 Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241001037736 Nocardia farcinica IFM 10152 Species 0.000 description 1
- 229920002332 Noncoding DNA Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100001279 PAM Human genes 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 241000601272 Parvibaculum lavamentivorans DS-1 Species 0.000 description 1
- 229940051027 Pasteurella multocida Drugs 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000981393 Persephonella marina Species 0.000 description 1
- 108091007151 Piwi-interacting RNA Proteins 0.000 description 1
- 210000002706 Plastids Anatomy 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000773205 Pseudarthrobacter chlorophenolicus A6 Species 0.000 description 1
- 241000695265 Pseudoalteromonas atlantica T6c Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000647111 Rhodococcus erythropolis PR4 Species 0.000 description 1
- 241001459443 Rhodococcus jostii RHA1 Species 0.000 description 1
- 241001113889 Rhodococcus opacus B4 Species 0.000 description 1
- 241001303434 Rhodopseudomonas palustris BisB18 Species 0.000 description 1
- 241001303431 Rhodopseudomonas palustris BisB5 Species 0.000 description 1
- 241000134686 Rhodospirillum rubrum ATCC 11170 Species 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 210000003705 Ribosomes Anatomy 0.000 description 1
- 241000516659 Roseiflexus Species 0.000 description 1
- 241000504328 Roseiflexus castenholzii DSM 13941 Species 0.000 description 1
- 101700061430 SAT19 Proteins 0.000 description 1
- 210000003296 Saliva Anatomy 0.000 description 1
- 241000933177 Shewanella pealeana ATCC 700345 Species 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 241001496704 Slackia heliotrinireducens DSM 20476 Species 0.000 description 1
- 241000756832 Streptobacillus moniliformis DSM 12112 Species 0.000 description 1
- 229940030998 Streptococcus agalactiae Drugs 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241001209210 Streptococcus agalactiae A909 Species 0.000 description 1
- 241001540742 Streptococcus agalactiae NEM316 Species 0.000 description 1
- 229940115920 Streptococcus dysgalactiae Drugs 0.000 description 1
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 1
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 1
- 241001167808 Streptococcus gallolyticus UCN34 Species 0.000 description 1
- 241001147754 Streptococcus gordonii str. Challis Species 0.000 description 1
- 241000672607 Streptococcus mutans NN2025 Species 0.000 description 1
- 229940076156 Streptococcus pyogenes Drugs 0.000 description 1
- 241000103155 Streptococcus pyogenes MGAS10270 Species 0.000 description 1
- 241000103160 Streptococcus pyogenes MGAS10750 Species 0.000 description 1
- 241000103154 Streptococcus pyogenes MGAS2096 Species 0.000 description 1
- 241001520169 Streptococcus pyogenes MGAS315 Species 0.000 description 1
- 241001148739 Streptococcus pyogenes MGAS5005 Species 0.000 description 1
- 241001332083 Streptococcus pyogenes MGAS6180 Species 0.000 description 1
- 241000103156 Streptococcus pyogenes MGAS9429 Species 0.000 description 1
- 241001496716 Streptococcus pyogenes NZ131 Species 0.000 description 1
- 241001455236 Streptococcus pyogenes SSI-1 Species 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 241000192593 Synechocystis sp. PCC 6803 Species 0.000 description 1
- 101700081234 TTR Proteins 0.000 description 1
- 101710025594 TUBB3 Proteins 0.000 description 1
- 102100008054 TUBB3 Human genes 0.000 description 1
- 241000520824 Thermobrachium celere Species 0.000 description 1
- 241001496699 Thermomonospora curvata DSM 43183 Species 0.000 description 1
- 229940094937 Thioredoxin Drugs 0.000 description 1
- 241000322994 Tolumonas auensis DSM 9187 Species 0.000 description 1
- 241000999858 Treponema denticola ATCC 35405 Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710028079 UMAG_05828 Proteins 0.000 description 1
- DRTQHJPVMGBUCF-UCVXFZOQSA-N Uridine Natural products O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- 229940045145 Uridine Drugs 0.000 description 1
- 241000847071 Verminephrobacter eiseniae EF01-2 Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 210000002845 Virion Anatomy 0.000 description 1
- 229920002533 WHP Posttrascriptional Response Element Polymers 0.000 description 1
- 241000605939 Wolinella succinogenes Species 0.000 description 1
- 241000883281 [Clostridium] cellulolyticum H10 Species 0.000 description 1
- 241000714896 [Eubacterium] rectale ATCC 33656 Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000001464 adherent Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 229920002092 cellular RNA Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N dCyd Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- 230000000994 depressed Effects 0.000 description 1
- 102000004419 dihydrofolate reductase family Human genes 0.000 description 1
- 108020001096 dihydrofolate reductase family Proteins 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 244000005702 human microbiome Species 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl β-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229920001239 microRNA Polymers 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- -1 mutant forms thereof Proteins 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000001177 retroviral Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- UKNAYQWNMMGCNX-UHFFFAOYSA-N sodium;[hydroxy(phenyl)methyl]-oxido-oxophosphanium Chemical compound [Na+].[O-][P+](=O)C(O)C1=CC=CC=C1 UKNAYQWNMMGCNX-UHFFFAOYSA-N 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- 102000002933 thioredoxin family Human genes 0.000 description 1
- 108060008226 thioredoxin family Proteins 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 241001496653 uncultured Termite group 1 bacterium phylotype Rs-D17 Species 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
- C12Y306/04013—RNA helicase (3.6.4.13)
Abstract
Methods and compositions of altering a eukaryotic cell are described including providing to the eukaryotic cell a guide DNA sequence complementary to a target nucleic acid sequence, providing to the eukaryotic cell an Ago enzyme or a nuclease null Ago protein that interacts with the guide DNA sequence for DNA-guided gene editing and regulation of the target nucleic acid sequence in a site specific manner.
Description
DNA-GUIDED GENE EDITING AND REGULATION
RELATED APPLICATION DATA
This application claims priority to U.S. Provisional Application No. 62/292,962 filed on February 9, 2016 and to U.S. Provisional Application No. 62/396,418 filed on September 19, 2016 which are hereby incorporated herein by reference in their entirety for all purposes.
STATEMENT OF GOVERNMENT INTERESTS
This invention was made with government support under Grant No. P50 HG005550 from the National Institutes of Health. The government has certain rights in the invention.
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on February 7, 2017, is named 010498_00905-WO_SL.txt and is 26,801 bytes in size.
BACKGROUND
Argonaute (Ago) proteins, involved in RNA interference pathways, use small single- stranded RNA (ssRNA) to facilitate RNA interference of complementary ssRNA targets. See G. Meister, Argonaute proteins: functional insights and emerging roles. Nature reviews. Genetics 14, 447-459 (2013). Ago from T. thermophiles (TtAgo) was reported to prevent infection and propagation of foreign DNA by loading 5'-phosphorylated small interfering DNA (siDNA) guides approximately 20 base pairs (bp) in length to cut complementary single stranded DNA. See D. C. Swarts, M. M. Jore, E. R. Westra, Y. Zhu, J. H. Janssen, A. P. Snijders, Y. Wang, D. J. Patel, J. Berenguer, S. J. Brouns, J. van der Oost, DNA-guided DNA
interference by a prokaryotic Argonaute. Nature 507, 258-261 (2014); G. Sheng, H. Zhao, J. Wang, Y. Rao, W. Tian, D. C. Swarts, J. van der Oost, D. J. Patel, Y. Wang, Structure-based cleavage mechanism of Thermus thermophilus Argonaute DNA guide strand-mediated DNA target cleavage. Proc Natl Acad Sci U S A 111, 652-657 (2014); K. Nakanishi, D. E. Weinberg, D. P. Bartel, D. J. Patel, Structure of yeast Argonaute with guide RNA. Nature 486, 368-374 (2012); Y. Wang, S. Juranek, H. Li, G. Sheng, T. Tuschl, D. J. Patel, Structure of an argonaute silencing complex with a seed-containing guide DNA and target RNA duplex. Nature 456, 921-926 (2008).
SUMMARY
Aspects of the present disclosure are directed to a method of altering genomic nucleic acids in a eukaryotic cell using an Argonaute (Ago) protein and a guide DNA which form a complex with a target nucleic acid sequence. According to one aspect, an Ago system, i.e. one or more guide DNA and an Ago protein and/or alternatively a donor nucleic acid sequence, are provided to a eukaryotic cell to a target nucleic acid sequence. According to this aspect, the Ago system is used to cut or nick the target nucleic acid sequence or otherwise deliver a transcriptional regulator, such as a transcriptional activator or transcriptional repressor, to the target nucleic acid sequence, or otherwise insert the donor nucleic acid into the target nucleic acid sequence.
According to certain aspects, a method of modulating expression of a target nucleic acid sequence in a eukaryotic cell is provided including introducing into the cell a first foreign nucleic acid encoding one or more guide DNAs complementary to one or more target nucleic acids, introducing into the cell a second foreign nucleic acid encoding an Ago protein, such as an Ago enzyme, an Ago nuclease or a nuclease null Ago protein, introducing into the cell a third foreign nucleic acid encoding a transcriptional regulator protein or domain, wherein the Ago protein and the transcriptional regulator protein or domain are expressed,
wherein the one or more guide DNAs, the Ago protein and the transcriptional regulator protein or domain co-localize to the target nucleic acid sequence and wherein the transcriptional regulator protein or domain regulates expression of the target nucleic acid sequence.
According to certain aspects, a method of integrating foreign DNA into a nucleic acid sequence of a eukaryotic cell is provided including providing to the cell a guide DNA sequence complementary to a target nucleic acid sequence, providing to the cell a donor sequence, providing to the cell an Ago enzyme that interacts with the guide DNA sequence and cleaves the target nucleic acid sequence in a site specific manner, wherein the guide DNA sequence binds to the complementary target nucleic acid sequence and the Ago enzyme cleaves the target nucleic acid sequence in a site specific manner; and wherein the donor sequence is integrated into the target nucleic acid sequence.
According to one aspect, the foreign nucleic acid encoding the Ago protein further encodes the transcriptional regulator protein or domain to create an expression product or fusion of the Ago protein attached to the transcriptional regulator protein or domain. According to this aspect, a third foreign nucleic acid encoding a transcriptional regulator or domain is not utilized. According to one aspect, the foreign nucleic acid further encodes a target of an RNA-binding domain and the foreign nucleic acid encoding the transcriptional regulator protein or domain further encodes an RNA-binding domain fused to the transcriptional regulator protein or domain. In this aspect, the guide DNA and the expressed transcriptional regulator protein or domain connect via the target of the RNA-binding domain and the RNA-binding domain. Other methods of linking a guide DNA and a transcriptional regulator protein or domain are known to those of skill in the art.
According to one aspect, the transcriptional regulator protein or domain is a transcriptional activator. According to one aspect, the transcriptional regulator protein or
domain upregulates expression of the target nucleic acid sequence. According to one aspect, the transcriptional regulator protein or domain upregulates expression of the target nucleic acid sequence to treat a disease or detrimental condition. According to one aspect, the target nucleic acid sequence is associated with a disease or detrimental condition. According to one aspect, the transcriptional regulator protein or domain is a transcriptional repressor.
According to one aspect, the transcriptional regulator protein or domain downregulates expression of the target nucleic acid sequence. According to one aspect, the transcriptional regulator protein or domain downregulates expression of the target nucleic acid sequence to treat a disease or detrimental condition. According to one aspect, the target nucleic acid sequence is associated with a disease or detrimental condition. According to one aspect, the transcriptional regulator or domain is a chromatin modifier, remodeller, or histone modifier including enzymes involved in histone acetylation, methylation, demethylation, phosphorylation, ubiquitination, sumoylation, ADP-ribosylation, deimination, and proline isomerization. According to one aspect, the transcriptional regulator protein or domain upregulates expression of the target nucleic acid sequence. According to one aspect, the transcriptional regulator protein or domain upregulates expression of the target nucleic acid sequence to treat a disease or detrimental condition.
According to one aspect of altering a target nucleic acid, two or more guide DNAs may be used with an Ago nuclease wherein the Ago nuclease co-localizes with the two or more guide DNAs to the target nucleic acid sequence and cuts the target nucleic acid sequence resulting in two or more adjacent cuts. According to one aspect, the two or more adjacent cuts are on the same strand of the double stranded target nucleic acid sequence. According to one aspect, the two or more adjacent cuts are on the same strand of the double stranded target nucleic acid sequence and result in homologous recombination. According to one aspect, the two or more adjacent cuts are on different strands of the double stranded
target nucleic acid sequence. According to one aspect, the two or more adjacent cuts are on different strands of the double stranded target nucleic acid sequence and create double stranded breaks. According to one aspect, the two or more adjacent cuts are on different strands of the double stranded target nucleic acid sequence and create double stranded breaks resulting in nonhomologous end joining. According to one aspect, the two or more adjacent cuts are on different strands of the double stranded target nucleic acid sequence and are offset with respect to one another. According to one aspect, the two or more adjacent cuts are on different strands of the double stranded target nucleic acid sequence and are offset with respect to one another and create double stranded breaks. According to one aspect, the two or more adjacent cuts are on different strands of the double stranded target nucleic acid sequence and are offset with respect to one another and create double stranded breaks resulting in nonhomologous end joining.
According to one aspect, the two or more adjacent cuts are on different strands of the double stranded target nucleic acid and create double stranded breaks resulting in fragmentation of the target nucleic acid sequence thereby preventing expression of the target nucleic acid sequence.
According to one aspect, the method further includes introducing into the cell a third foreign nucleic acid encoding a donor nucleic acid sequence wherein the two or more cuts results in incorporation of the donor nucleic acid sequence into the target nucleic acid sequence through homologous recombination or nonhomologous end joining.
According to one aspect, a method of altering a eukaryotic cell is provided including the steps of providing to the eukaryotic cell a guide DNA sequence complementary to a target nucleic acid sequence, providing to the eukaryotic cell an Ago enzyme that interacts with the guide DNA sequence and cleaves the target nucleic acid sequence in a site specific manner,
wherein the guide DNA sequence binds to the complementary target nucleic acid sequence and the Ago enzyme cleaves the target nucleic acid sequence in a site specific manner.
According to one aspect, methods described herein include providing a helicase to the cell where the helicase unwinds a helicase targeting target nucleic acid sequence. According to one aspect, methods described herein include providing a helicase to the cell where the helicase unwinds a helicase targeting target nucleic acid sequence where the helicase targeting nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart. According to one aspect, methods described herein include providing a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and the guide RNA targeting target nucleic acid sequence is unwound. According to one aspect, methods described herein include providing a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and the guide RNA targeting target nucleic acid sequence is unwound, and wherein the guide RNA targeting target nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart. According to one aspect, methods described herein include providing a donor sequence and wherein the donor sequence is inserted into the target nucleic acid sequence. According to one aspect, methods described herein include providing a plurality of guide DNAs into the cell that are complementary to different target nucleic acid sequences and the Ago enzyme cleaves the different target nucleic acid sequences in a site specific manner. According to methods described herein, the eukaryotic cell is a yeast cell, a plant cell, a mammalian cell or a human cell.
Further features and advantages of certain embodiments of the present invention will become more fully apparent in the following description of embodiments and drawings thereof, and from the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publications with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. The foregoing and other features and advantages of the present embodiments will be more fully understood from the following detailed description of illustrative embodiments taken in conjunction with the accompanying drawings in which:
Fig. 1 depicts results of a gel shifting assay (SEQ ID NOS 96, 97, 98, and 25, respectively, in order of appearance).
Fig. 2A to Fig. 2D are directed to engineered TtAgONN-VP64 activating human endogenous genes. Fig. 2A is a schematic depicting construction of TtAgo-VP64 having a CMV promoter driving an Ago double mutant D478A, D546A to remove nuclease activity fused with VP64 transcriptional domain with nuclear localization signal (NLS). Fig. 2B is a schematic of siDNA (guide DNA) targeted to TFAM promoter for activation of genomic locus. TFAM-7 and TFAM-8 were designed to target the promoter region of TFAM in the genome, 148 bp and 200 bp upstream of the transcriptional start site, respectively. Fig. 2C depicts data demonstrating that a TtAgo-VP64 system activates TFAM similarly to Cas9ST- VP64 system as measured by RT-QPCR of TFAM. Fig. 2D depicts data demonstrating that activation of endogenous genes decreases with the GC% of the 5'-phosphorylated 20bp siDNA. A reverse correlation of GC% of siDNA targeting sequence with TtAgo- VP64/siDNA activation activities was observed.
Fig. 3A depicts a schematic of guide RNA designed to localize nuclease null Cas9 at various distances from TtAgo-VP64/siDNA_TFAM-4. Fig. 3B depicts data of Fold TFAM Activation.
Fig. 4 depicts immunoblots and data of DNA-guided activation TFAM (25 kDa).
Fig. 5 is directed to data demonstrating that DNA-guided TtAgONN-VP64 activates a panel of genes. 3-6 siDNA targeting sequences were designed for the promoter region of 9 genes. The melting temperature (Tm), which is expressed as GC%, of each siDNA affects the efficiency of endogenous activation. All levels of activation were measured by RT-QPCR and normalized to experiments transfected by TtAgONN-VP64 alone. The 18s housekeeping gene was used as a control. Plotted values represent the average. Error bars represent the standard deviation from the mean (N=3).
Fig. 6 is directed to data demonstrating that DNA-guided TtAgONN represses a panel of genes. 3 siDNA targeting sequences were designed for exon 1 or 2 of 9 genes. GC% of each siDNA is listed. All levels of suppression were normalized to experiments transfected by TtAgONN alone. The 18s housekeeping gene was used as a control. Plotted values represent the average. Error bars represent the standard deviation from the mean (N=3).
Fig. 7 depicts data 5 depicts data for TtAgONN-VP64/siDNA sequence specificity as measured by TFAM activation activities by TtAgONN-VP64/siDNA coupled with different siDNAs (SEQ ID NOS 99, 23, 100, and 101, respectively, in order of appearance).
DETAILED DESCRIPTION
Embodiments of the present disclosure are directed to methods of targeting one or more target nucleic acid sequences for editing or transcriptional regulation using an Ago protein and a guide DNA.
According to one aspect, an Ago system, i.e. an Ago enzyme and a guide DNA sequence, is provided to a eukaryotic cell. The guide DNA sequence and the Ago enzyme co-localize to the target nucleic acid sequence or otherwise co-localize with the target nucleic acid sequence, and the Ago cuts or cleaves the target nucleic acid sequence in a site specific manner. The Ago enzyme and the guide DNA sequence are referred to as a co-localization complex as that term is understood by one of skill in the art to the extent that the guide RNA and the Ago enzyme complex with a target nucleic acid sequence.
According to one aspect, an Ago system, i.e. an Ago enzyme and a guide DNA sequence, is provided to a eukaryotic cell. A donor nucleic acid sequence is also provided to the cell. The guide DNA sequence and the Ago enzyme co-localize to the target nucleic acid sequence or otherwise co-localize with the target nucleic acid sequence, and the Ago cuts or cleaves the target nucleic acid sequence in a site specific manner. The donor nucleic acid is inserted into the target nucleic acid sequence, such as by homologous recombination or nonhomologous end joining. The Ago enzyme and the guide DNA sequence are referred to as a co-localization complex as that term is understood by one of skill in the art to the extent that the guide DNA sequence and the Ago enzyme complex with a target nucleic acid sequence.
According to one aspect, an Ago system, i.e. an Ago enzyme and a guide DNA sequence, is provided to a eukaryotic cell. A donor nucleic acid sequence is also provided to the cell, such as by being attached, connected or otherwise bound to either the Ago enzyme or the guide DNA sequence. The guide DNA sequence and the Ago enzyme co-localize to the target nucleic acid sequence or otherwise co-localize with the target nucleic acid sequence, and the Ago cuts or cleaves the target nucleic acid sequence in a site specific manner. The donor nucleic acid sequence is inserted into the target nucleic acid sequence, such as by homologous recombination or non-homologous end joining. The Ago enzyme and the guide
DNA sequence are referred to as a co-localization complex as that term is understood by one
of skill in the art to the extent that the guide DNA sequence and the Ago enzyme complex with a target nucleic acid sequence.
According to one aspect, an Ago system, i.e. a nuclease null Ago protein, i.e., an Ago protein that lacks enzymatic activity, and a guide DNA sequence, is provided to a eukaryotic cell. A transcriptional regulator is also provided to the cell. The guide DNA sequence and the nuclease null Ago protein co-localize to the target nucleic acid sequence or otherwise co- localize with the target nucleic acid sequence, and the transcriptional regulator regulates expression of the target nucleic acid sequence. The nuclease null Ago protein and the guide DNA sequence are referred to as a co-localization complex as that term is understood by one of skill in the art to the extent that the guide DNA sequence and the nuclease null Ago protein complex with a target nucleic acid sequence.
According to one aspect, an Ago system, i.e. an Ago nuclease and a guide DNA sequence, is provided to a eukaryotic cell. The guide DNA sequence and the Ago nuclease co-localize to the target nucleic acid sequence or otherwise co-localize with the target nucleic acid sequence, and the Ago nuclease cuts the target nucleic acid sequence in a site specific manner. According to one aspect, an Ago system, i.e. an Ago nuclease and a two or more guide DNA sequences, is provided to a eukaryotic cell. The guide DNA sequences and the Ago nuclease co-localize to target nucleic acid sequences at locations determined by the two guide DNA sequences or otherwise co-localize with the target nucleic acid sequences at locations determined by the two guide DNA sequences, and the Ago nuclease cuts the target nucleic acid at two adjacent sites. According to one aspect, a donor nucleic acid sequence may be provided which is inserted into the target nucleic acid sequence, such as by homologous recombination or non-homologous end joining. The Ago nuclease and the guide DNA sequence are referred to as a co-localization complex as that term is understood by one
of skill in the art to the extent that the guide RNA and the Ago nuclease complex with a target nucleic acid.
According to one aspect, any of the methods using an Ago system described herein may also be used with a helicase. According to this aspect, the helicase is provided to the cell and may be used to unwind a target nucleic acid to facilitate the Ago system with cutting, nicking or delivering a transcriptional regulator to the target nucleic acid sequence. A suitable helicase is a nuclease null Cas9 protein. Such a nuclease null Cas9 protein can be used with a guide RNA to form a co-localization complex at or with a target nucleic acid sequence so as to unwind the target nucleic acid sequence into two separate single strand portions of the double stranded target nucleic acid. The unwound target nucleic acid sequence then facilitates co-localization of an Ago system at or near the target nucleic acid sequence.
According to one aspect, a eukaryotic cell is provided including a first nucleic acid sequence that is complementary to a target nucleic acid sequence, a second nucleic acid sequence encoding an Ago enzyme that interacts with the first nucleic acid sequence and cleaves the target nucleic acid sequence in a site specific manner, wherein the first nucleic acid sequence is a guide DNA, and wherein the cell expresses the Ago enzyme, and wherein the guide DNA binds to the complementary target nucleic acid and the Ago enzyme cleaves the target nucleic acid sequence in a site specific manner. In one embodiment, the eukaryotic cell is a yeast cell, a plant cell or a mammalian cell. In another embodiment, the eukaryotic cell is a human cell. In one embodiment, the eukaryotic cell further includes a plurality of nucleic acids encoding a plurality of guide DNA sequences complementary to different target nucleic acid sequences. In another embodiment, the eukaryotic cell of further comprises a helicase where the helicase unwinds a helicase targeting target nucleic acid sequence. In yet another embodiment, the eukaryotic cell further comprises a helicase where the helicase
unwinds a helicase targeting target nucleic acid sequence where the helicase targeting nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart. In another embodiment, the eukaryotic cell further comprises a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide RNA targeting target nucleic acid sequence. In a further embodiment, the eukaryotic cell further comprises a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide RNA targeting target nucleic acid sequence, and wherein the guide RNA targeting target nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart. In another embodiment, the eukaryotic cell further comprises a donor sequence and wherein the donor sequence is inserted into the target nucleic acid sequence.
According to another aspect, a eukaryotic cell is provided including a first nucleic acid sequence that is complementary to a target nucleic acid sequence, a second nucleic acid sequence encoding a nuclease null Ago protein, wherein the nuclease null Ago protein includes a transcriptional regulator domain connected thereto for modulating target nucleic acid expression, wherein the guide DNA and the nuclease null Ago protein including the transcriptional regulator domain co-localize at the target nucleic acid sequence and wherein the transcriptional regulator domain modulates expression of the target nucleic acid sequence. In one embodiment, the eukaryotic cell further comprises a helicase where the helicase unwinds a helicase targeting target nucleic acid sequence. In another embodiment, the
eukaryotic cell further comprises a helicase where the helicase unwinds a helicase targeting target nucleic acid sequence where the helicase targeting nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart. In one embodiment, the eukaryotic cell further comprises a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide RNA targeting target nucleic acid sequence. In another embodiment, the eukaryotic cell further comprises a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide RNA targeting target nucleic acid sequence, and wherein the guide RNA targeting target nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart. In one embodiment, the transcriptional regulator is a transcriptional activator or a transcriptional repressor. In another embodiment, the eukaryotic cell further comprises a plurality of guide DNAs that are complementary to different target nucleic acid sequences and the nuclease null Ago protein modulates expression of the different target nucleic acid sequences in a site specific manner. In one embodiment, the eukaryotic cell is a yeast cell, a plant cell or a mammalian cell. In another embodiment, the eukaryotic cell is a human cell.
According to one aspect, one or more vectors are used to introduce one or more nucleic acids encoding an Ago system, i.e. an Ago protein and a guide DNA sequence, and optionally a donor nucleic acid sequence, into a eukaryotic cell for editing or transcriptional regulation. A transcriptional regulator may be provided to the cell separately or may be
attached, connected or otherwise bound to either the Ago protein or the guide DNA for delivery to the target nucleic acid sequence to be regulated. The nucleic acids are expressed and the Ago system cuts or nicks the target nucleic acid sequence or otherwise delivers a transcriptional regulator to the target nucleic acid sequence. Together, a guide DNA and an Ago protein are referred to as a co-localization complex as that term is understood by one of skill in the art to the extent that the guide DNA sequence and the Ago protein complex with a target nucleic acid sequence. According to certain aspects, a vector may include one or more nucleic acids encoding an Ago protein, a guide DNA, a donor nucleic acid sequence and/or a transcriptional regulator. The vectors may include any additional genetic regulatory elements as known to those of skill in the art, such as regulators, promoters, nuclear localization signals (NLS), start codons, stop codons, a transgene etc. According to certain aspects, one or more nucleic acids encoding an Ago protein, a guide DNA sequence, a donor nucleic acid sequence and/or a transcriptional regulator may be present within the same vector or present within different vectors.
Vectors according to the present disclosure include those known in the art as being useful in delivering genetic material into a cell and would include regulators, promoters, nuclear localization signals (NLS), start codons, stop codons, a transgene etc., and any other genetic elements useful for integration and expression, as are known to those of skill in the art.
AGO DESCRIPTION
Argonaute (Ago) proteins, involved in RNA interference pathways, use small single- stranded RNA (ssRNA) to facilitate RNA interference of complementary ssRNA targets. See G. Meister, Argonaute proteins: functional insights and emerging roles. Nature reviews. Genetics 14, 447-459 (2013). Ago from T. thermophiles (TtAgo) was reported to prevent
infection and propagation of foreign DNA by loading 5'-phosphorylated small interfering DNA (siDNA) guides approximately 20 base pairs (bp) in length to cut complementary single stranded DNA. See D. C. Swarts, M. M. Jore, E. R. Westra, Y. Zhu, J. H. Janssen, A. P. Snijders, Y. Wang, D. J. Patel, J. Berenguer, S. J. Brouns, J. van der Oost, DNA-guided DNA interference by a prokaryotic Argonaute. Nature 507, 258-261 (2014); G. Sheng, H. Zhao, J. Wang, Y. Rao, W. Tian, D. C. Swarts, J. van der Oost, D. J. Patel, Y. Wang, Structure-based cleavage mechanism of Thermus thermophilus Argonaute DNA guide strand-mediated DNA target cleavage. Proc Natl Acad Sci U S A 111, 652-657 (2014); K. Nakanishi, D. E. Weinberg, D. P. Bartel, D. J. Patel, Structure of yeast Argonaute with guide RNA. Nature 486, 368-374 (2012); Y. Wang, S. Juranek, H. Li, G. Sheng, T. Tuschl, D. J. Patel, Structure of an argonaute silencing complex with a seed-containing guide DNA and target RNA duplex. Nature 456, 921-926 (2008).
An exemplary Ago protein is Ago from Thermus thermophiles (TtAgo) or a modification or homolog thereof. Sequences of Ago protein species are known to those of skill in the art. According to one aspect, the Ago enzyme, or the nuclease null Ago includes homologs and orthologs thereof and which retain the ability of the protein to bind to the DNA and be guided by the guide DNA sequence. According to one aspect, the Ago protein includes the sequence as known for naturally occurring Thermus thermophiles Ago and protein sequences having at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% homology thereto and being a DNA binding protein. According to one aspect, the Ago protein includes protein sequences having at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% homology to the naturally occurring Thermus thermophiles Ago and being a DNA binding protein. An exemplary Ago protein is Ago from haloalkaliphilic archaebacterium N. gregoryi SP2 (NgAgo) or a modification or homolog thereof. A non-exhaustive list of protein sequences that have been identified as relevant Ago
proteins by searching the public databases such as (NCBI, GENBANK and UniProt) with the
TtAgo sequence is provided below.
Piwi domain protein 1.50E-19 T CAG:1329
Halopiger xanaduensis (strain
F8D8G0_HALX Stem cell self-renewal protein
DSM 18323 / JCM 14033 / SH- 1.20E-18 S Piwi
6)
Q53W94_THE Thermus thermophilus (strain
Uncharacterized protein O.OOE+00 T9 HB8 / ATCC 27634 / DSM 579)
Pyrococcus furiosus (strain
Q8U3D2_PYR
Uncharacterized protein ATCC 43587 / DSM 3638 / O.OOE+00 FU JCM 8422 / Vcl)
Stanieria cyanosphaera
K9XZC6_STAC Stem cell self-renewal protein
(strain ATCC 29371 / PCC O.OOE+00 8 Piwi
7437)
Synechococcus sp. (strain
B1XJG0_SYNP
Uncharacterized protein ATCC 27264 / PCC 7002 / PR- O.OOE+00 3
6)
A0A0C1VHB4 Lyngbya confervoides
Uncharacterized protein O.OOE+00 _9CYAN BDU 141952
E0UCX3_CYAP Stem cell self-renewal protein Cyanothece sp. (strain PCC
O.OOE+00 3 Piwi domain protein 7822)
Synechococcus sp. (strain JA-
Q2JI93_SYNJB Piwi domain protein O.OOE+00
2-3B'a(2-13))
Q8DKB1_THE Thermosynechococcus
TII0948 protein O.OOE+00 EB elongatus (strain BP-1)
Q31N05_SYN Synechococcus elongatus
Uncharacterized protein O.OOE+00 E8 (strain PCC 7942)
Q53W94_THE Thermus thermophilus (strain
Uncharacterized protein O.OOE+00 T9 HB8 / ATCC 27634 / DSM 579)
Pyrococcus furiosus (strain
Q8U3D2_PYR
Uncharacterized protein ATCC 43587 / DSM 3638 / O.OOE+00 FU JCM 8422 / Vcl)
Stanieria cyanosphaera
K9XZC6_STAC Stem cell self-renewal protein
(strain ATCC 29371 / PCC O.OOE+00 8 Piwi
7437)
Synechococcus sp. (strain
B1XJG0_SYNP
Uncharacterized protein ATCC 27264 / PCC 7002 / PR- O.OOE+00 3
6)
A0A0C1VHB4 Lyngbya confervoides
Uncharacterized protein O.OOE+00 _9CYAN BDU 141952
E0UCX3_CYAP Stem cell self-renewal protein Cyanothece sp. (strain PCC
O.OOE+00 3 Piwi domain protein 7822)
Synechococcus sp. (strain JA-
Q2JI93_SYNJB Piwi domain protein O.OOE+00
2-3B'a(2-13))
Q8DKB1_THE Thermosynechococcus
TII0948 protein O.OOE+00 EB elongatus (strain BP-1)
Q31N05_SYN Synechococcus elongatus
Uncharacterized protein O.OOE+00 E8 (strain PCC 7942)
D3S0S6_FERP Stem cell self-renewal protein Ferroglobus placidus (strain
O.OOE+00 A Piwi domain protein DSM 10642 / AEDII 12DO)
Methanocaldococcus
Uncharacterized protein jannaschii (strain ATCC 43067
Y1321_METJA O.OOE+00
MJ1322 / DSM 2661 / JAL-l / JCM
10045 / N BRC 100440)
Thermogladius cellulolyticus
I3TE64_THEC2 Uncharacterized protein O.OOE+00
(strain 1633)
Q5P0R2_ARO Aromatoleum aromaticum
Uncharacterized protein O.OOE+00 AE (strain EbN l)
Natrinema pellirubrum (strain
L0JS08_NATP
Uncharacterized protein DSM 15624 / JCM 10476 / O.OOE+00 2
NCIMB 786)
R5NJJ8_9FIR
Uncharacterized protein Eubacterium sp. CAG:604 O.OOE+00 M
Q53W94_THE Thermus thermophilus (strain
Uncharacterized protein O.OOE+00 T9 HB8 / ATCC 27634 / DSM 579)
Pyrococcus furiosus (strain
Q8U3D2_PYR
Uncharacterized protein ATCC 43587 / DSM 3638 / O.OOE+00 FU JCM 8422 / Vcl)
Stanieria cyanosphaera
K9XZC6_STAC Stem cell self-renewal protein
(strain ATCC 29371 / PCC O.OOE+00 8 Piwi
7437)
Synechococcus sp. (strain
B1XJG0_SYNP
Uncharacterized protein ATCC 27264 / PCC 7002 / PR- O.OOE+00 3
6)
A0A0C1VHB4 Lyngbya confervoides
Uncharacterized protein O.OOE+00 _9CYAN BDU 141952
E0UCX3_CYAP Stem cell self-renewal protein Cyanothece sp. (strain PCC
O.OOE+00 3 Piwi domain protein 7822)
Synechococcus sp. (strain JA-
Q2JI93_SYNJB Piwi domain protein O.OOE+00
2-3B'a(2-13))
Q8DKB1_THE Thermosynechococcus
TII0948 protein O.OOE+00 EB elongatus (strain BP-1)
Q31N05_SYN Synechococcus elongatus
Uncharacterized protein O.OOE+00 E8 (strain PCC 7942)
D3S0S6_FERP Stem cell self-renewal protein Ferroglobus placidus (strain
O.OOE+00 A Piwi domain protein DSM 10642 / AEDII 12DO)
Q53W94_THE Thermus thermophilus (strain
Uncharacterized protein O.OOE+00 T9 HB8 / ATCC 27634 / DSM 579)
Q8U3D2_PYR Pyrococcus furiosus (strain
Uncharacterized protein O.OOE+00 FU ATCC 43587 / DSM 3638 /
JCM 8422 / Vcl)
Stanieria cyanosphaera
K9XZC6_STAC Stem cell self-renewal protein
(strain ATCC 29371 / PCC O.OOE+00 8 Piwi
7437)
Synechococcus sp. (strain
B1XJG0_SYNP
Uncharacterized protein ATCC 27264 / PCC 7002 / PR- O.OOE+00 3
6)
A0A0C1VHB4 Lyngbya confervoides
Uncharacterized protein O.OOE+00 _9CYAN BDU 141952
E0UCX3_CYAP Stem cell self-renewal protein Cyanothece sp. (strain PCC
O.OOE+00 3 Piwi domain protein 7822)
Synechococcus sp. (strain JA-
Q2JI93_SYNJB Piwi domain protein O.OOE+00
2-3B'a(2-13))
Q8DKB1_THE Thermosynechococcus
TII0948 protein O.OOE+00 EB elongatus (strain BP-1)
Q31N05_SYN Synechococcus elongatus
Uncharacterized protein O.OOE+00 E8 (strain PCC 7942)
D3S0S6_FERP Stem cell self-renewal protein Ferroglobus placidus (strain
O.OOE+00 A Piwi domain protein DSM 10642 / AEDII 12DO)
Methanocaldococcus
Uncharacterized protein jannaschii (strain ATCC 43067
Y1321_METJA O.OOE+00
MJ1322 / DSM 2661 / JAL-1 / JCM
10045 / N BRC 100440)
Thermogladius cellulolyticus
I3TE64_THEC2 Uncharacterized protein O.OOE+00
(strain 1633)
Q5P0R2_ARO Aromatoleum aromaticum
Uncharacterized protein O.OOE+00 AE (strain EbN l)
Natrinema pellirubrum (strain
L0JS08_NATP
Uncharacterized protein DSM 15624 / JCM 10476 / O.OOE+00 2
NCIMB 786)
R5NJJ8_9FIR
Uncharacterized protein Eubacterium sp. CAG:604 O.OOE+00 M
R7RTW6_9CL Thermobrachium celere DSM
Uncharacterized protein O.OOE+00 OT 8683
Q53W94_THE Thermus thermophilus (strain
Uncharacterized protein O.OOE+00 T9 HB8 / ATCC 27634 / DSM 579)
Pyrococcus furiosus (strain
Q8U3D2_PYR
Uncharacterized protein ATCC 43587 / DSM 3638 / O.OOE+00 FU JCM 8422 / Vcl)
Stanieria cyanosphaera
K9XZC6_STAC Stem cell self-renewal protein
(strain ATCC 29371 / PCC O.OOE+00 8 Piwi
7437)
Synechococcus sp. (strain
B1XJG0_SYNP
Uncharacterized protein ATCC 27264 / PCC 7002 / PR- O.OOE+00 3
6)
A0A0C1VHB4 Lyngbya confervoides
Uncharacterized protein O.OOE+00 _9CYAN BDU 141952
Q53W94_THE Thermus thermophilus (strain
Uncharacterized protein O.OOE+00 T9 HB8 / ATCC 27634 / DSM 579)
Pyrococcus furiosus (strain
Q8U3D2_PYR
Uncharacterized protein ATCC 43587 / DSM 3638 / O.OOE+00 FU JCM 8422 / Vcl)
Stanieria cyanosphaera
K9XZC6_STAC Stem cell self-renewal protein
(strain ATCC 29371 / PCC O.OOE+00 8 Piwi
7437)
Synechococcus sp. (strain
B1XJG0_SYNP
Uncharacterized protein ATCC 27264 / PCC 7002 / PR- O.OOE+00 3
6)
A0A0C1VHB4 Lyngbya confervoides
Uncharacterized protein O.OOE+00 _9CYAN BDU 141952
It is well known in the art that eukaryotic Argonaute proteins are involved in small RNA-mediated silencing mechanisms such as RNA interference (RNAi), microRNA repression and piRNA-mediated transposon silencing. Argonautes bind small RNAs that guide them to RNA targets in order to regulate gene expression and repress invasive genomic elements. Carthew RW, Sontheimer EJ., Origins and Mechanisms of miRNAs and siRNAs, Cell. Vol. 136, Pp 642-655, (2009). Prokaryotic Argonaute proteins are found in many bacterial and archaeal species and are well documented in the art. Exemplary prokaryotic Argonaute proteins described in the following references including supplementary information are hereby incorporated by reference in their entireties. For example, bioinformatics analysis and the phylogenetic distribution of Argonaute proteins in bacteria and archaea indicate that about 20% of sequenced strains contain at least one Ago gene. Makarova KS, et al., Prokaryotic homologs of Argonaute proteins are predicted to function as key components of a novel system of defense against mobile genetic elements. Biology direct. 4:29, (2009). Molloy S, Bacterial argonaute sets sail, Nature Reviews Microbiology,
Vol. 11, Pp 743, (2013). Bacterial Aquifex aeolicus and archaeal Pyrococcus furiosus Ago proteins have also been reported and well known, e.g., via structural studies. Song JJ, et al., Crystal structure of Argonaute and its implications for RISC slicer activity, Science, Vol. 305, Pp 1434-1437, (2004). Yuan YR, et al., Crystal structure of A. aeolicus argonaute, a site- specific DNA-guided endoribonuclease, provides insights into RISC-mediated mRNA cleavage, Mol Cell, Vol. 19, Pp 405-419, (2005). It has been known in the art that several prokaryotic Agos, unlike their eukaryotic counterparts, bind single- stranded DNA guides in vitro for cleavage of RNA targets. The presence of an Ago gene correlated with other known genome protection systems suggests roles of prokaryotic Agos for protecting cells from invasive nucleic acids.
Argonautes have also been known in the gram-negative bacteria Rhodobacter sphaeroides (RsAgo) and Thermus thermophilus (TtAgo). Olovnikov I, et al., Bacterial argonaute samples the transcriptome to identify foreign DNA, Molecular cell, Vol. 51, Pp: 594-605, (2013). Swarts DC, et al. DNA-guided DNA interference by a prokaryotic Argonaute, Nature, Vol. 507, Pp: 258-261, (2014). These Agos from both bacterial species directly target DNA molecules and protect the genome against foreign and possibly invasive genomic elements, such as plasmids. However, there are important differences between Agos from both bacterial species in that RsAgo uses small RNAs as guide molecules, whereas TtAgo uses small DNAs as guide molecules. The Ago 5' binding pocket discriminates its guide by the nature of the first nucleotide. For example, in Rhodobacter sphaeroides, there is a strong nucleotide bias for uridine at the 5' position for Rs Ago- associated small RNA guide molecules. Whereas in Thermus thermophiles, there is a strong nucleotide bias for deoxycytidine at the 5' position for TtAgo-associated small DNA guide molecules. In the case of TtAgo, its endonuclease activity cleaves DNA targets in the middle of the region targeted by the guide DNA. Unlike the CRISPR-Cas system, which is another
prokaryotic genomic host defense system, where effector proteins associate with host- encoded RNA guides to determine DNA cleavage loci, the Agos in both bacteria Rhodobacter sphaeroides and Thermus thermophilus recognize properties inherent to invading DNAs and silence them without using small RNA or DNA guides encoded in separate genomic loci. Hur, JK., et al., Prokaryotic Argonautes defend genomes against invasive DNA, Trends Biochem ScL, June, Vol. 39(6): 257-259, (2014), Wiedenheft B, et al., RNA-guided genetic silencing systems in bacteria and archaea, Nature, Vol. 482, Pp 331-338, (2012).
According to certain aspects, an Ago enzyme is altered or otherwise modified to inactivate the nuclease activity. Such alteration or modification includes altering one or more amino acids to inactivate the nuclease activity or the nuclease domain. For example, modifications at D478A and D546A result in a nuclease null Ago protein. Such modification includes removing the polypeptide sequence or polypeptide sequences exhibiting nuclease activity, i.e. the nuclease domain, such that the polypeptide sequence or polypeptide sequences exhibiting nuclease activity, i.e. nuclease domain, are absent from the Ago protein. Other modifications to inactivate nuclease activity will be readily apparent to one of skill in the art based on the present disclosure. The nuclease-null Ago protein retains the ability to bind to DNA even though the nuclease activity has been inactivated. Accordingly, the nuclease null Ago protein includes the polypeptide sequence or sequences required for DNA binding but may lack the one or more or all of the nuclease sequences exhibiting nuclease activity or may be altered to render the nuclease sequences inactive.
According to certain aspects, the Ago protein may be delivered directly to a cell as a native species by methods known to those of skill in the art, including injection or lipofection, or as transcribed from its cognate DNA, with the cognate DNA introduced into
cells through electroporation, transient and stable transfection (including lipofection) and viral transduction.
According to one aspect, the Ago protein is exogenous to the cell. According to one aspect, the Ago protein is foreign to the cell. According to one aspect, the Ago protein is non-naturally occurring within the cell.
According to one aspect, the nucleic acid sequence encoding the TtAgo protein or its variants is codon optimized for optimal host cell expression. In one embodiment, the nucleic acid sequence encoding the TtAgo protein or its variants is codon optimized for human cell expression.
CAS9 HELICASE DESCRIPTION
Cas9 proteins and Type II CRISPR systems are well documented in the art. See Makarova et al., Nature Reviews, Microbiology, Vol. 9, June 2011, pp. 467-477 including all supplementary information hereby incorporated by reference in its entirety.
In general, bacterial and archaeal CRISPR-Cas systems rely on short guide RNAs in complex with Cas proteins to direct degradation of complementary sequences present within invading foreign nucleic acid. See Deltcheva, E. et al. CRISPR RNA maturation by trans- encoded small RNA and host factor RNase III. Nature 471, 602-607 (2011); Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proceedings of the National Academy of Sciences of the United States of America 109, E2579-2586 (2012); Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012); Sapranauskas, R. et al. The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic acids research 39, 9275- 9282 (2011); and Bhaya, D., Davison, M. & Barrangou, R. CRISPR-Cas systems in bacteria
and archaea: versatile small RNAs for adaptive defense and regulation. Annual review of genetics 45, 273-297 (2011). A recent in vitro reconstitution of the S. pyogenes type II CRISPR system demonstrated that crRNA ("CRISPR RNA") fused to a normally trans- encoded tracrRNA ("trans-activating CRISPR RNA") is sufficient to direct Cas9 protein to sequence-specifically cleave target DNA sequences matching the crRNA. Expressing a gRNA homologous to a target site results in Cas9 recruitment and degradation of the target DNA. See H. Deveau et al. , Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. Journal of Bacteriology 190, 1390 (Feb, 2008).
Three classes of CRISPR systems are generally known and are referred to as Type I, Type II or Type III). According to one aspect, a particular useful enzyme according to the present disclosure to cleave dsDNA is the single effector enzyme, Cas9, common to Type II. See K. S. Makarova et al , Evolution and classification of the CRISPR-Cas systems. Nature reviews. Microbiology 9, 467 (Jun, 2011) hereby incorporated by reference in its entirety. Within bacteria, the Type II effector system consists of a long pre-crRNA transcribed from the spacer-containing CRISPR locus, the multifunctional Cas9 protein, and a tracrRNA important for gRNA processing. The tracrRNAs hybridize to the repeat regions separating the spacers of the pre-crRNA, initiating dsRNA cleavage by endogenous RNase III, which is followed by a second cleavage event within each spacer by Cas9, producing mature crRNAs that remain associated with the tracrRNA and Cas9. TracrRNA-crRNA fusions are contemplated for use in the present methods.
Cas9 unwinds the DNA duplex and searches for sequences matching the crRNA to cleave. Target recognition occurs upon detection of complementarity between a "protospacer" sequence in the target DNA and the remaining spacer sequence in the crRNA. Importantly, Cas9 cuts the DNA only if a correct protospacer- adjacent motif (PAM) is also present at the 3' end. According to certain aspects, different protospacer-adjacent motif can
be utilized. For example, the S. pyogenes system requires an NGG sequence, where N can be any nucleotide. S. thermophilus Type II systems require NGGNG (see P. Horvath, R. Barrangou, CRISPR/Cas, the immune system of bacteria and archaea. Science 327, 167 (Jan 8, 2010) hereby incorporated by reference in its entirety and NNAGAAW (see H. Deveau et al. , Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. Journal of bacteriology 190, 1390 (Feb, 2008) hereby incorporatd by reference in its entirety), respectively, while different S. mutans systems tolerate NGG or NAAR (see J. R. van der Ploeg, Analysis of CRISPR in Streptococcus mutans suggests frequent occurrence of acquired immunity against infection by M102-like bacteriophages. Microbiology 155, 1966 (Jun, 2009) hereby incorporated by refernece in its entirety. Bioinformatic analyses have generated extensive databases of CRISPR loci in a variety of bacteria that may serve to identify additional useful PAMs and expand the set of CRISPR-targetable sequences (see M. Rho, Y. W. Wu, H. Tang, T. G. Doak, Y. Ye, Diverse CRISPRs evolving in human microbiomes. PLoS genetics 8, el002441 (2012) and D. T. Pride et al. , Analysis of streptococcal CRISPRs from human saliva reveals substantial sequence diversity within and between subjects over time. Genome research 21, 126 (Jan, 2011) each of which are hereby incorporated by reference in their entireties.
In S. pyogenes, Cas9 generates a blunt-ended double- stranded break 3bp upstream of the pro tospacer- adjacent motif (PAM) via a process mediated by two catalytic domains in the protein: an HNH domain that cleaves the complementary strand of the DNA and a RuvC-like domain that cleaves the non-complementary strand. See Jinek et al., Science 337, 816-821 (2012) hereby incorporated by reference in its entirety. Cas9 proteins are known to exist in many Type II CRISPR systems including the following as identified in the supplementary information to Makarova et al., Nature Reviews, Microbiology, Vol. 9, June 2011, pp. 467- 477: Methanococcus maripaludis C7; Corynebacterium diphtheriae; Corynebacterium
efficiens YS-314; Corynebacterium glutamicum ATCC 13032 Kitasato; Corynebactenum glutamicum ATCC 13032 Bielefeld; Corynebacterium glutamicum R; Corynebacterium kroppenstedtii DSM 44385; Mycobacterium abscessus ATCC 19977; Nocardia farcinica IFM10152; Rhodococcus erythropolis PR4; Rhodococcus jostii RHA1; Rhodococcus opacus B4 uid36573; Acidothermus cellulolyticus 11B; Arthrobacter chlorophenolicus A6; Kribbella flavida DSM 17836 uid43465; Thermomonospora curvata DSM 43183; Bifidobacterium dentium Bdl; Bifidobacterium longum DJO10A; Slackia heliotrinireducens DSM 20476; Persephonella marina EX HI; Bacteroides fragilis NCTC 9434; Capnocytophaga ochracea DSM 7271; Flavobacterium psychrophilum JIP02 86; Akkermansia muciniphila ATCC BAA 835; Roseiflexus castenholzii DSM 13941; Roseiflexus RSI; Synechocystis PCC6803; Elusimicrobium minutum Peil91; uncultured Termite group 1 bacterium phylotype Rs D17; Fibrobacter succinogenes S85; Bacillus cereus ATCC 10987; Listeria innocua;Lactobacillus casei; Lactobacillus rhamnosus GG; Lactobacillus salivarius UCC118; Streptococcus agalactiae A909; Streptococcus agalactiae NEM316; Streptococcus agalactiae 2603; Streptococcus dysgalactiae equisimilis GGS 124; Streptococcus equi zooepidemicus MGCS10565; Streptococcus gallolyticus UCN34 uid46061; Streptococcus gordonii Challis subst CHI; Streptococcus mutans NN2025 uid46353; Streptococcus mutans; Streptococcus pyogenes Ml GAS; Streptococcus pyogenes MGAS5005; Streptococcus pyogenes MGAS2096; Streptococcus pyogenes MGAS9429; Streptococcus pyogenes MGAS 10270; Streptococcus pyogenes MGAS6180; Streptococcus pyogenes MGAS315; Streptococcus pyogenes SSI-1; Streptococcus pyogenes MGAS 10750; Streptococcus pyogenes NZ131; Streptococcus thermophiles CNRZ1066; Streptococcus thermophiles LMD-9; Streptococcus thermophiles LMG 18311; Clostridium botulinum A3 Loch Maree; Clostridium botulinum B Eklund 17B; Clostridium botulinum Ba4 657; Clostridium botulinum F Langeland; Clostridium cellulolyticum H10; Finegoldia magna ATCC 29328; Eubacterium rectale
ATCC 33656; Mycoplasma gallisepticum; Mycoplasma mobile 163K; Mycoplasma penetrans; Mycoplasma synoviae 53; Streptobacillus moniliformis DSM 12112; Bradyrhizobium BTAil; Nitrobacter hamburgensis X14; Rhodopseudomonas palustris BisB18; Rhodopseudomonas palustris BisB5; Parvibaculum lavamentivorans DS-1; Dinoroseobacter shibae DFL 12; Gluconacetobacter diazotrophicus Pal 5 FAPERJ; Gluconacetobacter diazotrophicus Pal 5 JGI; Azospirillum B510 uid46085; Rhodospirillum rubrum ATCC 11170; Diaphorobacter TPSY uid29975; Verminephrobacter eiseniae EF01-2; Neisseria meningitides 053442; Neisseria meningitides alphal4; Neisseria meningitides Z2491 ; Desulfo vibrio salexigens DSM 2638; Campylobacter jejuni doylei 269 97; Campylobacter jejuni 81116; Campylobacter jejuni; Campylobacter lari RM2100; Helicobacter hepaticus; Wolinella succinogenes; Tolumonas auensis DSM 9187; Pseudoalteromonas atlantica T6c; Shewanella pealeana ATCC 700345; Legionella pneumophila Paris; Actinobacillus succinogenes 130Z; Pasteurella multocida; Francisella tularensis novicida U112; Francisella tularensis holarctica; Francisella tularensis FSC 198; Francisella tularensis tularensis; Francisella tularensis WY96-3418; and Treponema denticola ATCC 35405. The Cas9 protein may be referred by one of skill in the art in the literature as Csnl. An exemplary S. pyogenes Cas9 protein sequence is provided in Deltcheva et al., Nature All, 602-607 (2011) hereby incorporated by reference in its entirety.
Modification to the Cas9 protein is a representative embodiment of the present disclosure. CRISPR systems useful in the present disclosure are described in R. Barrangou, P. Horvath, CRISPR: new horizons in phage resistance and strain identification. Annual review of food science and technology 3, 143 (2012) and B. Wiedenheft, S. H. Sternberg, J. A. Doudna, RNA-guided genetic silencing systems in bacteria and archaea. Nature 482, 331 (Feb 16, 2012) each of which are hereby incorporated by reference in their entireties.
According to certain aspects, Cas9 is altered or otherwise modified to inactivate the
nuclease activity. Such alteration or modification includes altering one or more amino acids to inactivate the nuclease activity or the nuclease domain. Such modification includes removing the polypeptide sequence or polypeptide sequences exhibiting nuclease activity, i.e. the nuclease domain, such that the polypeptide sequence or polypeptide sequences exhibiting nuclease activity, i.e. nuclease domain, are absent from the DNA binding protein. Other modifications to inactivate nuclease activity will be readily apparent to one of skill in the art based on the present disclosure. Accordingly, a nuclease-null DNA binding protein, such as a nuclease null Cas9 protein, includes polypeptide sequences modified to inactivate nuclease activity or removal of a polypeptide sequence or sequences to inactivate nuclease activity. The nuclease-null Cas9 retains the ability to bind to DNA even though the nuclease activity has been inactivated. Accordingly, the nuclease null Cas9 includes the polypeptide sequence or sequences required for DNA binding but may lack the one or more or all of the nuclease sequences exhibiting nuclease activity.
According to an additional aspect, nuclease-null Cas9 proteins are provided where one or more amino acids in Cas9 are altered or otherwise removed to provide nuclease-null Cas9 proteins. According to one aspect, the amino acids include D10 and H840. See Jinek et al., Science 337, 816-821 (2012). According to an additional aspect, the amino acids include D839 and N863. According to one aspect, one or more or all of D10, H840, D839 and H863 are substituted with an amino acid which reduces, substantially eliminates or eliminates nuclease activity. According to one aspect, one or more or all of D10, H840, D839 and H863 are substituted with alanine. According to one aspect, a Cas9 protein having one or more or all of D10, H840, D839 and H863 substituted with an amino acid which reduces, substantially eliminates or eliminates nuclease activity, such as alanine, is referred to as a nuclease-null Cas9 ("Cas9Nuc") and exhibits reduced or eliminated nuclease activity, or nuclease activity is absent or substantially absent within levels of detection. According to
this aspect, nuclease activity for a Cas9Nuc may be undetectable using known assays, i.e. below the level of detection of known assays.
An exemplary CRISPR system includes the S. pyogenes Cas9 nuclease (Sp. Cas9), an extremely high-affinity (see Sternberg, S.H., Redding, S., Jinek, M., Greene, E.C. & Doudna, J.A. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 507, 62-67 (2014) hereby incorporated by reference in its entirety), programmable DNA-binding protein isolated from a type II CRISPR-associated system (see Garneau, J.E. et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468, 67-71 (2010) and Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012) each of which are hereby incorporated by reference in its entirety). According to certain aspects, a nuclease null or nuclease deficient Cas 9 can be used in the methods described herein. Such nuclease null or nuclease deficient Cas9 proteins are described in Gilbert, L.A. et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442-451 (2013); Mali, P. et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature biotechnology 31, 833-838 (2013); Maeder, M.L. et al. CRISPR RNA-guided activation of endogenous human genes. Nature methods 10, 977-979 (2013); and Perez-Pinera, P. et al. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nature methods 10, 973-976 (2013) each of which are hereby incorporated by reference in its entirety. The DNA locus targeted by Cas9 (and by its nuclease-deficient mutant, "dCas9" precedes a three nucleotide (nt) 5 NGG-3 ' "PAM" sequence, and matches a 15-22-nt guide or spacer sequence within a Cas9-bound RNA cof actor, referred to herein and in the art as a guide RNA. Altering this guide RNA is sufficient to target Cas9 or a nuclease deficient Cas9 to a target nucleic acid. In a multitude of CRISPR-based biotechnology applications (see Mali, P., Esvelt, K.M. & Church, G.M. Cas9 as a versatile tool for
engineering biology. Nature methods 10, 957-963 (2013); Hsu, P.D., Lander, E.S. & Zhang, F. Development and Applications of CRISPR-Cas9 for Genome Engineering. Cell 157, 1262- 1278 (2014); Chen, B. et al. Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 155, 1479-1491 (2013); Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014); Wang, T., Wei, J.J., Sabatini, D.M. & Lander, E.S. Genetic screens in human cells using the CRISPR- Cas9 system. Science 343, 80-84 (2014); Nissim, L., Perli, S.D., Fridkin, A., Perez-Pinera, P. & Lu, T.K. Multiplexed and Programmable Regulation of Gene Networks with an Integrated RNA and CRISPR Cas Toolkit in Human Cells. Molecular cell 54, 698-710 (2014); Ryan, O.W. et al. Selection of chromosomal DNA libraries using a multiplex CRISPR system. eLife 3 (2014); Gilbert, L.A. et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell (2014); and Citorik, R.J., Mimee, M. & Lu, T.K. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nature biotechnology (2014) each of which are hereby incorporated by reference in its entirety), the guide is often presented in a so-called sgRNA (single guide RNA), wherein the two natural Cas9 RNA cofactors (gRNA and tracrRNA) are fused via an engineered loop or linker.
According to certain aspects, the helicase, such as a nuclease null Cas9, may be delivered directly to a cell as a native species by methods known to those of skill in the art, including injection or lipofection, or as transcribed from its cognate DNA, with the cognate DNA introduced into cells through electroporation, transient and stable transfection (including lipofection) and viral transduction.
According to one aspect, the Cas9 protein is exogenous to the cell. According to one aspect, the Cas9 protein is foreign to the cell. According to one aspect, the Cas9 protein is non-naturally occurring within the cell.
GUIDE DNA DESCRIPTION
Embodiments of the present disclosure are directed to the use of an Ago system and, in particular, a guide DNA which includes a spacer sequence. The term spacer sequence is understood by those of skill in the art and may include any polynucleotide having sufficient complementarity with a target nucleic acid sequence to hybridize with the target nucleic acid sequence and direct sequence-specific binding of an Ago protein to the target nucleic acid sequence. According to certain aspects, the spacer sequence is between about 1 and about 5 nucleotides in length. Aspects of the present disclosure are directed to methods of making or providing such guide DNA sequences as described herein by expressing constructs encoding such guide DNA using promoters and terminators and optionally other genetic elements as described herein.
According to certain aspects, the guide DNA may be delivered directly to a cell as a native species by methods known to those of skill in the art, including injection or lipofection, or as transcribed from its cognate DNA, with the cognate DNA introduced into cells through electroporation, transient and stable transfection (including lipofection) and viral transduction.
According to one aspect, an exemplary guide DNA is a 5'-phosphorylated DNA sequence. According to one aspect, an exemplary guide DNA is a 20bp DNA sequence. According to one aspect, an exemplary guide DNA is a 5'-phosphorylated 20bp DNA sequence. According to one aspect, the spacer sequence need not hybridize 100% to the target nucleic acid sequence. According to one aspect, the spacer sequence may include between 1 to 5 mismatches with the target nucleic acid sequence.
According to one aspect, the guide DNA is exogenous to the cell. According to one aspect, the guide DNA is foreign to the cell. According to one aspect, the guide DNA is non- naturally occurring within the cell.
DONOR DESCRIPTION
The term "donor nucleic acid" includes a nucleic acid sequence which is to be inserted into a target nucleic acid sequence which has been cut or nicked according to methods described herein. The donor nucleic acid sequence may be expressed by the cell.
According to one aspect, the donor nucleic acid is exogenous to the cell. According to one aspect, the donor nucleic acid is foreign to the cell. According to one aspect, the donor nucleic acid is non-naturally occurring within the cell.
TRANSCRIPTION REGULATOR DESCRIPTION
According to one aspect, an engineered Ago protein and guide DNA system is provided which enables DNA-guided nucleic acid regulation, such as genomic DNA regulation, in eukaryotic cells by tethering transcriptional regulatory proteins or domains to either a nuclease-null Ago protein or to a guide DNA. According to one aspect of the present disclosure, one or more transcriptional regulatory proteins or domains (such terms are used interchangeably) are joined or otherwise connected to a nuclease-deficient or nuclease null Ago protein or one or more guide DNA (gDNA). The transcriptional regulatory domains correspond to targeted loci. Accordingly, aspects of the present disclosure include methods and materials for localizing transcriptional regulatory domains to targeted loci by fusing, connecting or joining such domains to either a nuclease null Ago or to the gDNA.
According to one aspect, a nuclease null Ago-transcriptional regulator fusion capable of transcriptional regulation, either transcriptional activation or transcriptional repression, is provided. According to one aspect, a VP64 activation domain is joined, fused, connected or otherwise tethered to the C terminus of a nuclease null Ago protein. According to one method, the transcriptional regulatory domain is provided to the site of a target nucleic acid
sequence by the nuclease null Ago protein and a guide DNA. According to one method, a nuclease null Ago protein attached, connected, bound or fused to a transcriptional regulatory domain is provided within a cell along with one or more guide DNA sequences. The nuclease null Ago protein with the transcriptional regulatory domain attached, connected, bound or fused thereto co-localize with a guide DNA at or near a target nucleic acid sequence. The transcriptional regulatory domain regulates expression of the target nucleic acid sequence. According to a specific aspect, a nuclease null Ago-VP64 construct activates transcription of a gene, such as a reporter construct, when combined with a gDNA(s) targeting a sequence(s) near the promoter, thereby displaying DNA-guided transcriptional activation. According to a specific aspect, a nuclease null Ago-repressor construct represses transcription of a gene, such as a reporter construct, when combined with a gDNA(s) targeting a sequence(s) near the promoter, thereby displaying DNA-guided transcriptional repression. According to a specific aspect, a nuclease null Ago represses transcription of a gene, such as a reporter construct, when combined with a gDNA(s) targeting a sequence(s) near the promoter, thereby displaying DNA-guided transcriptional repression by blocking transcription due to binding.
According to one aspect, a gDNA-transcriptional regulator fusion capable of transcriptional regulation, either transcriptional activation or transcriptional repression, is provided. According to one aspect, a VP64 activation domain is joined, fused, connected or otherwise tethered to a gDNA sequence. According to one method, the transcriptional regulatory domain is provided to the site of a target nucleic acid sequence by the guide DNA sequence. According to one method, a nuclease null Ago protein is provided within a cell along with a guide DNA sequence attached, connected, bound or fused to a transcriptional regulatory domain. The nuclease null Ago protein co-localizes with a guide DNA at or near a target nucleic acid sequence. The transcriptional regulatory domain regulates expression of
the target nucleic acid sequence. According to a specific aspect, a gDNA-VP64 construct activates transcription of a gene, such as a reporter construct, when co-localized with a nuclease null Ago targeting a sequence(s) near the promoter, thereby displaying DNA-guided transcriptional activation. According to a specific aspect, a gDNA-repressor construct represses transcription of a gene, such as a reporter construct, when co-localized with a nuclease null Ago targeting a sequence(s) near the promoter, thereby displaying DNA-guided transcriptional repression.
Transcriptional regulator proteins or domains which are transcriptional activators include VP16 and VP64 and others readily identifiable by those skilled in the art based on the present disclosure.
According to one aspect, the transcriptional regulator or domain is a chromatin modifier, remodeller, or histone modifier including enzymes involved in histone acetylation, methylation, demethylation, phosphorylation, ubiquitination, sumoylation, ADP-ribosylation, deimination, and proline isornerization. Exemplary regulators include DNA methyltransferases, histone methyltransferases and demethylases, histone acetyltransferase and deacetylases, etc. are well known in the art. Non-limiting disclosures as found in the following references are hereby incorporated by reference in their entireties. Taiping Chen & Sharon Y. R. Dent, Chromatin modifiers and remodellers: regulators of cellular differentia don, Nature Reviews Genetics, Vol. 15, Pp: 93-106 (2014). Andrew J Bannister and Tony Kouzarides, Regulation of chromatin by histone modifications, Cell Research, Vol. 21, Pp 381-395, (2011).
According to one aspect, the transcriptional regulator protein or domain upregulates expression of the target nucleic acid sequence.
According to one aspect, the transcriptional regulator protein or domain upregulates expression of the target nucleic acid sequence to treat a disease or detrimental condition.
According to one aspect, the transcriptional regulator is exogenous to the cell. According to one aspect, the transcriptional regulator is foreign to the cell. According to one aspect, the transcriptional regulator is non-naturally occurring within the cell.
TARGET NUCLEIC ACID SEQUENCE
A target nucleic acid sequence includes any nucleic acid sequence, such as a genomic nucleic acid sequence or a gene to which a co-localization complex as described herein can be useful to either cut, nick or regulate. Target nucleic acids include nucleic acid sequences capable of being expressed into proteins. According to one aspect, the target nucleic acid is genomic DNA, mitochondrial DNA, plastid DNA, viral DNA, exogenous DNA or cellular RNA.
For purposes of the present disclosure, DNA, such as genomic DNA, can include the target nucleic acid sequence and a co-localization complex can bind to or otherwise co- localize with the target nucleic acid sequence or adjacent or near the target nucleic acid sequence and in a manner in which the co-localization complex may have a desired effect on the target nucleic acid sequence. One of skill based on the present disclosure will readily be able to identify or design guide DNAs and Ago proteins which co-localize to a target nucleic acid sequence. According to one aspect, the target nucleic acid is an A-T rich nucleic acid sequence with an initiating 5'- phosphorylated nucleotide C.
FOREIGN NUCLEIC ACIDS DESCRIPTION
Foreign nucleic acids (i.e. those which are not part of a cell's natural nucleic acid composition) may be introduced into a cell using any method known to those skilled in the art for such introduction. Such methods include transfection, transduction, viral transduction, microinjection, lipofection, nucleofection, nanoparticle bombardment, transformation, conjugation and the like. One of skill in the art will readily understand and adapt such
methods using readily identifiable literature sources. According to one aspect, a foreign nucleic acid is exogenous to the cell. According to one aspect, a foreign nucleic acid is non- naturally occurring within the cell.
CELLS
Cells according to the present disclosure include any cell into which foreign nucleic acids can be introduced and expressed as described herein. It is to be understood that the basic concepts of the present disclosure described herein are not limited by cell type. Cells according to the present disclosure include eukaryotic cells, prokaryotic cells, animal cells, plant cells, fungal cells, archael cells, eubacterial cells and the like. Cells include eukaryotic cells such as yeast cells, plant cells, and animal cells. Particular cells include mammalian cells. Further, cells include any in which it would be beneficial or desirable to cut, nick or regulate a target nucleic acid. Such cells may include those which are deficient in expression of a particular protein leading to a disease or detrimental condition. Such diseases or detrimental conditions are readily known to those of skill in the art. According to the present disclosure, the nucleic acid responsible for expressing the particular protein may be targeted by the methods described herein and a transcriptional activator resulting in upregulation of the target nucleic acid and corresponding expression of the particular protein. In this manner, the methods described herein provide therapeutic treatment. Such cells may include those which over express a particular protein leading to a disease or detrimental condition. Such diseases or detrimental conditions are readily known to those of skill in the art. According to the present disclosure, the nucleic acid responsible for expressing the particular protein may be targeted by the methods described herein and a transcriptional depressor resulting in downregulation of the target nucleic acid and corresponding expression of the particular protein. In this manner, the methods described herein provide therapeutic treatment.
According to one aspect, the cell is a eukaryotic cell or a prokaryotic cell. According to one aspect, the cell is a yeast cell, bacterial cell, fungal cell, a plant cell or an animal cell. According to one aspect, the cell is a mammalian cell. According to one aspect, the cell is a human cell. According to one aspect, the cell is a stem cell whether adult or embryonic. According to one aspect, the cell is a pluripotent stem cell. According to one aspect, the cell is an induced pluripotent stem cell. According to one aspect, the cell is a human induced pluripotent stem cell. According to one aspect, the cell is in vitro, in vivo or ex vivo.
VECTORS
Vectors are contemplated for use with the methods and constructs described herein. The term "vector" includes a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Vectors used to deliver the nucleic acids to cells as described herein include vectors known to those of skill in the art and used for such purposes. Certain exemplary vectors may be plasmids, lentiviruses or adeno-associated viruses known to those of skill in the art. Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art. One type of vector is a "plasmid," which refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g. retroviruses, lentiviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses). Viral vectors also include polynucleotides carried by a virus for transfection into a host cell. Certain vectors are capable of autonomous replication in a host cell into which they
are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors." Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
Methods of non-viral delivery of nucleic acids or native DNA binding protein, native guide RNA or other native species include lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam™ and Lipofectin™). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, WO 91/17424; WO 91/16024. Delivery can be to cells (e.g. in vitro or ex vivo administration) or target tissues (e.g. in vivo administration). The term native includes the protein, enzyme or guide RNA species itself and not the nucleic acid encoding the species.
REGULATORY ELEMENTS AND TERMINATORS AND TAGS
Regulatory elements are contemplated for use with the methods and constructs described herein. The term "regulatory element" is intended to include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poly-U sequences). Such regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). A tissue- specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes). Regulatory elements may also direct expression in a temporal- dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific. In some embodiments, a vector may comprise one or more pol III promoter (e.g. 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g. 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g. 1, 2, 3, 4, 5, or more pol I promoters), or combinations thereof. Examples of pol III promoters include, but are not limited to, U6 and HI promoters. Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EFla promoter and Pol II promoters
described herein. Also encompassed by the term "regulatory element" are enhancer elements, such as WPRE; CMV enhancers; the R-U5' segment in LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit β-globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc. A vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRISPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.).
Aspects of the methods described herein may make use of terminator sequences. A terminator sequence includes a section of nucleic acid sequence that marks the end of a gene or operon in genomic DNA during transcription. This sequence mediates transcriptional termination by providing signals in the newly synthesized mRNA that trigger processes which release the mRNA from the transcriptional complex. These processes include the direct interaction of the mRNA secondary structure with the complex and/or the indirect activities of recruited termination factors. Release of the transcriptional complex frees RNA polymerase and related transcriptional machinery to begin transcription of new mRNAs. Terminator sequences include those known in the art and identified and described herein.
Aspects of the methods described herein may make use of epitope tags and reporter gene sequences. Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Examples of reporter genes include, but are not limited to, glutathione-S- transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, betaglucuronidase, luciferase, green fluorescent protein (GFP), HcRed,
DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP).
DELIVERY DESCRIPTION
Embodiments of the present disclosure are directed to a method of delivering an Ago protein to cells within a subject comprising administering to the subject, such as systemically administering to the subject, such as by intravenous administration or injection, intraperitoneal administration or injection, intramuscular administration or injection, intracranial administration or injection, intraocular administration or injection, subcutaneous administration or injection, an Ago protein or a nucleic acid encoding the Ago protein.
Embodiments of the present disclosure are directed to a method of delivering a guide DNA to cells within a subject comprising administering to the subject, such as systemically administering to the subject, such as by intravenous administration or injection, intraperitoneal administration or injection, intramuscular administration or injection, intracranial administration or injection, intraocular administration or injection, subcutaneous administration or injection, a guide DNA or a nucleic acid encoding the guide DNA.
Embodiments of the present disclosure are directed to a method of delivering an Ago protein and a guide DNA to cells within a subject comprising administering to the subject, such as systemically administering to the subject, such as by intravenous administration or injection, intraperitoneal administration or injection, intramuscular administration or injection, intracranial administration or injection, intraocular administration or injection, subcutaneous administration or injection, an Ago protein or a nucleic acid encoding the Ago protein and a guide DNA or a nucleic acid encoding the guide DNA.
DISEASES AND CONDITIONS
Diseases and detrimental conditions may be characterized by abnormal loss of expression or underexpression of a particular protein or abnormal gain or overexpression of a particular protein. Such diseases or detrimental conditions can be treated by upregulation or down regulation of the particular protein. Accordingly, methods of treating a disease or detrimental condition are provided where the co-localization complex as described herein associates or otherwise binds to a target nucleic acid and the transcriptional activator of the co-localization complex upregulates expression of the target nucleic acid or the transcriptional repressor of the co-localization complex downregulates expression of the target nucleic acid. One of skill in the art will readily identify such diseases and detrimental conditions based on the present disclosure.
The following examples are set forth as being representative of the present disclosure. These examples are not to be construed as limiting the scope of the present disclosure as these and other equivalent embodiments will be apparent in view of the present disclosure, figures and accompanying claims.
EXAMPLE I
Materials and Methods
Cell lines
The 293 FT HEK cells were grown and maintained in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) high glucose supplemented with 10% fetal bovine serum (Invitrogen), penicillin/streptomycin (pen/strep, Invitrogen) and nonessential amino acids (Invitrogen).
Primer Design
List of primers used herein are provided below.
NCBI Gene Symbol Sequence SEQ ID NO:
TFAM TGGGAAGGTCTGGAGCA 1
GCCAAGACAGATGAAAACCAC 2
NANOG ATGTCTTCTGCTGAGATGCC 3
GAAGTGGGTTGTTTGCCTTTG 4
IL1B CAGCCAATCTTCATTGCTCAAG 5
GAACAAGTCATCCTCATTGCC 6
TERT CATGCCAAGCTCTCGCT 7
GATCTCCTCACGCAGACG 8
SOX2 GCCTCACTTACAAGACAGCTC 9
GCCTCCAAGACCTAGCCTA 10
KLF4 TTGACTTTGGGGTTCAGGTG 11
GCGAACGTGGAGAAAGATGG 12 cMYC TTCGGGTAGTGGAAAACCAG 13
CAGTAGAAATACGGCTGCAC 14
RNA18s5 GAGACTCTGGCATGCTAACTAG 15
GGACATCTAAGGGCATCACAG 16
HBG1 TGAATGTGGAAGATGCTGGA 17
TTGCCATGTGCCTTGACTT 18
Oct4 AATCCAGTCCCAGGACATCA 19
CGTTTGGCTGAATACCTTCC 20
ASCL GGAGCTTCTCGACTTCACCA 21
AACGCCACTGACAAGAAAGC 22 siDNA (guide DNA)
List of siDNAs used herein are provided below.
Nanog_l NANOG /5Phos/cagctacttttgcattacaat 42
Nanog_2 NANOG /5Phos/caggttctgttgctcggtttt 43
Nanog_3 NANOG /5Phos/cattcctgttgaaccatattc 44
Nanog_4 NANOG /5Phos/ctaatttttgtatttttagta 45
HBG1_1 HBG1 /5Phos/caatagtcttagagtatcca 46
HBG1_2 HBG2 /5Phos/caaaggctataaaaaaaatta 47
HBG1_3 HBG3 /5Phos/cagtttttctctaatttattc 48
HBG1_4 HBG4 /5Phos/caagaaggtaaaaaacggct 49
IL1B_1 IL1B /5Phos/cataaaaacagcgagggagaa 50
IL1B_2 IL1B /5Phos/caggtattcaacagagaaatt 51
IL1B_3 IL1B /5Phos/caatactcttttcccctttcc 52
IL1B_4 IL1B /5Phos/caggaaaacaatgcatatttg 53
TERT_1 TERT /5Phos/catagaaaacacaattttaaaa 54
TERT_2 TERT /5Phos/cagtttctgaaagtaggaaa 55
TERT_3 TERT /5Phos/catttcccaccctttctcga 56
TERT_4 TERT /5Phos/catttctctttgcaggttct 57
GDFl l-1 GDF11 /5phos/ atttttgtctccactctaac 58
GDF11-2 GDF11 /5phos/ ttcctccttcttggttctgt 59
GDF11-3 GDF11 /5phos/ tcttcttttcctcctttgtc 60
Cas9NN-VP64 system
SEQ
ID
Name of gRNA Gene gRNA targeting sequence PAM NO:
gRNA 2 TFAM ctcggagttcagaaatagta acggga 61 gRNA3 TFAM ttaagctctgcggtaaggcc ttggaa 62
SP1 TFAM acctaaaaatgcagattcca agg 63
SP2 TFAM cgcctctcccgttactattt ggg 64
SP3 TFAM acacacggaattaagctctg egg 65
SP4 TFAM tcgctaaaatgaagattaat ggg 66
SP5 TFAM ttagaacttgttaaattctg ggg 67
cmyc. l 80 /5Phos/ctggatttttttcgggtagt
cmyc.2 81 /5Phos/ctcaacgttagcttcaccaa
cmyc.3 82 /5Phos/cagccgtatttctactgcga
NANOG. l 83 /5Phos/cttgctttgaagcatccgac
NANOG.2 84 /5Phos/cttcacctatgcctgtgatt
NANOG.3 85 /5Phos/caaatgtcttctgctgagat
HBG1.1 86 /5Phos/catttcacagaggaggacaa
HBG1.2 87 15 Phos/ctggaggagaaaccctggga
HBG1.3 88 /5Phos/ctttgacagctttggcaacc
IL1B.1 89 /5Phos/ctcgccagtgaaatgatggc
IL1B.2 90 /5Phos/caatgaggatgacttgttct
IL1B.3 91 /5Phos/ctttgaagctgatggcccta
TERT. l 92 /5Phos/ctccccgctgccgagccgtg
TERT.2 93 /5Phos/ctgcgcagccactaccgcga
TERT.3 94 /5Phos/ctttccgcgcgctggtggcc
Plasmids
The ttAGo-VP64 and ttAgo fragments (Genewiz) were synthesized and cloned into pCdna3.1 topo ct-gfp (Invitrogen) plasmids according to the manufacture's' instruction. The sequence information of the vector is provided below.
ttAgo- VP64 sequence ( NLS-VP64 is highlighted in bold and italics)
ATGAACCACCTGGGTAAAACTGAAGTATTCCTGAACCGTTTCGCACTGagaccacttaat CCGGAAGAACTGCGTCCGTGGCGTCTGGAAGTTGTTCTGGACCCGCCGCCGGGTC GTGAAGAAGTTTACCCGCTGCTGGCTCAGGTTGCTCGTCGTGCTGGTGGTGTTAC
CGTTCGTATGGGTGACGGTCTGGCTTCTTGGTCTCCGCCGGAAgtattagtacttGAAGG
TACCCTGGCTCGTATGGGTCAGACCTACgcatatcgtttatatccaAAAGGTCGTCGTCCGCT
GgatccgaaggatcctGGTGAACGTTCTGTTCTGTCTgcattagctagaCGTCTGCTGCAGGAAC
GTCTGCGTCGTCTGGAAGGTGTTTGGGTTGAAGGTCTGGCTGTTTACCGTCGTGA
ACACGCTCGTGGTCCGGGTTGGCGTGTTCTGGGTGGTGCTGTTCTGGACCTGTGG
GTTTCTGACTCTGGTGCTTTCCTGCTGGAAGTTGACCCGGCTTACCGTATCCTGTG
CGAAATGTCTCTGGAAGCTTGGCTGGCTCAGGGTCACCCGCTGCCGAAACGTGTT
CGTAACGCTTACGACCGTCGTACCTGGGAActgctaagattaGGTGAAGAAGACCCGAA
AGAACTGCCGCTGCCGGGTGGTCTGTCTCTGCTGGACTACCACGCTTCTAAAGGT
CGTCTGCAGGGTCGTGAAggcgggagagtaGCTTGGGTTGCTGACCCGAAAGACCCGC
GTAAACCGATCCCGCACCTGACCGGTCTGCTGGTTCCGGTTCTGACCCTGGAAGA
CCTGCACGAGGAAGAAGGTTCTCTGGCTCTGTCTCTGCCGTGGGAAGAACGTCGT
CGTCGTACCCGTGAAATCGCTTCTTGGATCGGTCGTCGTCTGGGTCTGGGTACCC
CGGAAGCTGTTCGTGCTCAGGCTTACCGTCTGTCTATCCCGAAACTGATGGGTCG
TCGTGCTGTTTCTAAACCGGCTGACGCTCTGCGTGTTGGTTTCTACCGTGCTCAGG
AAACCgcgttagcccttttacgaCTGGACGGTGCTCAGGGTTGGCCGGAATTCCTGCGTCGG
GCTCTGCTGCGTGCTTTCGGTGCTTCTGGTGCTTCTCTGCGTCTGCACACCCTGCA
CGCTCACCCGTCTCAGGGTCTGGCTTTCCGTGAAGCTCTGCGTAAAGCTAAAGAA
GAAGGTGTTCAGGCTGTTCTGGTTCTGACCCCGCCGATGGCTTGGGAAGACCGTA
ACCGTCTGAAAGCTcttttactgagagagggcctgccgagcCAGATCCTGAACGTTCCGCTGCGT
GAAGAAGAACGTCACCGTTGGGAAAACGCTCTGCTGGGTCTGCTGGCTAAAGCT
GGTCTGCAGGTTGTTGCTCTGTCTGGTGCTTACCCGGCTGAACTGGCTGTTGGTTT
CGcCGCTGGTGGTCGTGAATCTTTCCGTTTCGGTGGTGCTGCTTGCGCTGTTGGTG
GTGACGGTGGTCACCTGCTGTGGACCCTGCCGGAAGCTCAGGCTGGTGAACGTA
TCCCGCAGGAAGTTGTTTGGGACCTGCTGGAAGAAACCCTGTGGGCTTTCCGTCG
TAAAGCTGGTCGTCTGCCGTCTCGTGTTCTGCTGCTGCGTGcCGGTCGTGTTCCGC
AGGACGAATTCGCTCTGGCTttagaagcgttagcgCGTGAAGGTATCGCTTACGACCTGGT
TTCTGTTCGTAAATCTGGTGGTGGTCGTGTTTACCCGGTTCAGGGTCGTCTGGCTG
ACGGTCTGTACGTTCCGCTGGAAGACAAAACCTTCCTGCTGCTGACCGTTCACCG
TGACTTCCGTGGTACCCCGCGTCCGCTGAAACTGGTTCACGAAGCTGGTGACACC
CCGCTGGAAGCTCTGGCTCACCAGATCTTCCACCTGACCCGTCTGTACCCGGCTT
CTGGTTTCGCTTTCCCGCGTCTGCCGGCTCCGCTGCACCTGGCTGACCGTCTGGTT
AAAGAAGTTGGTCGTCTGGGTATCCGTCACCTGAAAGAAGTTGACCGTGAAAAA YGTYCTYCGTTCCCAAGAAGAAGAGAAAGGTGGAGGCCAGCGGTTCCGGACGGG
CTGACGCATTGGACGATTTTGATCTGGATATGCTGGGAAGTGACGCCCTCGATGAT
TTTGA CCTTGA CA TGCTTGGTTCGGA TGCCCTTGA TGA CTTTGA CCTCGA CA TGCT
CGGCAGTGACGCCCTTGATGATTTCGACCTGGACATGCTGATTAAC (SEQ ID NO:
95)
Transfection and QPCR analysis
293 T reporter cells were seeded at densities of 5 *10 4cells per well in 96- well plate and transfected them with 300ng of each ttAgo-VP64 plasmid and 300ng siDNA using Lipofectamine 2000 following the manufacturer's protocols. The cells were harvested 36 hours after transfection and RT-QPCR was performed using cDNA to CT II kit (Invitrogen). All the RT-QPCR data is normalized with 18sRNA control and the sequence of the primers are provided herein.
Western blot
Cell harvest
7 million 293 T reporter cells were seeded in each T175 plate and were transfected with 12μg of TtAgo-VP64 plasmid and 12μg siDNA using 60μΙ. of Lipofectamine 2000 following the manufacturer's protocols. The cells were harvested 1 week after transfection by removing culture medium from the adherent cells, rinsing the cells in PBS, and adding M- PER (Pierce) reagent according to protocol. The lysate was collected and transferred into a microcentifuge tube. The samples were spun at 14,000 x g for 10 minutes at 4°C to pellet the cell debris. The supernatant was then transferred to another tube for analysis and frozen at - 20°C overnight.
Western blot
Supernatant was thawed on ice. The Pierce™ BCA Protein Assay Kit was used to quantify protein content (1: 12.5 dilution) in each sample according to the manufacturer's protocol. The samples were then normalized to lowest concentration. Next, Laemmli Buffer was added at 1:6 dilution and boiled at 95°C for 5 minutes. Gels were then loaded with 30 μΐ, of sample at 60 V to stack for 20 minutes and then 100 V for 1 hour. PVDF was pre-treated with 20% methanol and then transfer buffer (25 mM Tris, 192 mM glycine, 10% methanol). The wet transfer sandwich was then prepared according to manufacturer's protocol and transferred for 1 hour at 100 V. Membranes were then trimmed and incubated in 5% milk TBST (Tris- buffered saline, 0.1% Tween-20). The membrane was then incubated in either TFAM antibody (Aviva Systems Biology #OAAF02353 or Tubulin (TUBB3) antibody (Aviva Systems #OAAD00318) in 5% milk overnight at 4°C. The membranes were then washed 3 times in IX TBST for 5 minutes each. Next, the membranes were incubated in anti-Rabbit in 5% milk for 1 hour and washed 3 times for 5 minutes in IX TBST. The membranes were then exposed to the Bio-Rad Clarity™ ECL substrate according to manufacturer's instructions and imaged using x-ray film. Densitometry of each band was quantified using ImageJ toolkit.
Gel shifting assay
Protein Purification
Plasmid pWUR-702 and pWUR-703 containing strept-tagged TtAgo proteins from Addgene are transformed into Rosetta™ 2(DE3) strain (Agilent) and grown in 5 mL of 2YT media with 100 μg/mL of Spectinomycin overnight. 250 mL media are inoculated with the overnight cultures and protein expression is induced with 1 mM of IPTG at OD600 around 0.6-0.8. The cells are incubated at shaker at 20°C for 16 h and harvest by centrifuge. Cell pellet is then resuspended in Buffer A (20 mM Tris-HCl pH 7.6, 1 M NaCl and 2 mM MgCb) and lysed with french pressure cell. The protein is purified over 3 mL Strep-Tactin® Superflow® resin with protocol suggested by vendor. Protein are eluted into Buffer A plus 2.5 mM <i-Desthiobiotin and stored in -80°C upon adding one volume of 80 % glycerol.
Gel Shift Assay
5'-Biotinylated or unlabeled competing substrate ssDNA, dsDNA and 5'-phosphorylated guide DNA are purchased from Integrated DNA Technology without further purification. Binding reactions contain the following components: 1 μΜ of 5 '-biontin-substrate, 1 μΜ of guide DNA, 0.5 mg/mL of Salmon sperm DNA (Invitrogen), 5 μΜ of TtAgo protein, 100 μΜ of competing substrate (optional), 20 mM HEPES-KOH pH 7.6, 100 mM KC1, 5 mM MgCl2, 1 mM DTT. The reactions are incubated at 37 °C for 1 h and resolved on 6 % DNA retardation gel (Invitrogen) with running buffer containing IX TBE and 5 mM MgCb. The DNA are transferred to nitrocellulose membrane by iBlot (Invitrogen) dry transfer, cross- linked under UV and stained by the LightShift Chemiluminescent EMSA Kit (Thermo Scientific) according to vendor's manual instruction.
EXAMPLE II Engineered Ago and Guide DNA
A DNA-guided Ago system is provided for genome engineering. A TtAgo protein and siDNA components are engineered to both activate and repress gene expression in human cells. As indicated in Fig. 1, it was confirmed that TtAgo/siDNA has sequence specific single stranded DNA (ssDNA) binding activity in vitro at 37°C. Purified ttAgo protein was incubated with either a dsDNA (double stranded DNA) or ssDNA (single stranded DNA) substrate wt/wo siDNA at 37°C and the binding of ttAgo with the substrate was examined by gel shifting assay. Binding of ttAgo with ssDNA with the presence of siDNA (lane 9 from the left) was detected. The sequence of substrate and siDNA are identified in Fig. 1.
TtAgo/siDNA systems were engineered for gene suppression and activation in human cells. The gene suppression system features a CMV promoter driving a human optimized codon Ago double site mutant TtAgONN(D478A, D546A), which removes its nuclease activity, fused to a C-terminal SV40 nuclear localization signal (NLS). The activation system features an activation domain, VP64, on the C-terminus (Fig 2A). Guide siDNA were selected in AT rich sequences within the promoter (for activation) or exon 1/2 (for suppression) region with a 5'dC initiating nucleotide. See D. C. Swarts, M. M. Jore, E. R. Westra, Y. Zhu, J. H. Janssen, A. P. Snijders, Y. Wang, D. J. Patel, J. Berenguer, S. J. Brouns, J. van der Oost, DNA-guided DNA interference by a prokaryotic Argonaute. Nature 507, 258-261 (2014) hereby incorporated by reference in its entirety.
To test if TtAgONN-VP64/siDNA activates human endogenous genes, two siDNAs (siDNA TFAM-7 and siDNA TFAM-8) were designed to target the promoter regions of transcription factor A mitochondria (TFAM). See Fig. 2B and sequences provided below.
TFAM- 8 TFAM /5Phos/cacggaattaagctctgcgg 27
Name Gene gRNA targeting sequence for CRISPR/Cas-ST PAM
gRNA 2 TFAM ctcggagttcagaaatagta acggga 61 gRNA 3 TFAM ttaagctctgcggtaaggcc ttggaa 62
As a comparison, we designed two Streptococcus thermophiles Cas9-VP64 (Cas9ST- VP64)/gRNA constructs were designed according to K. M. Esvelt, P. Mali, J. L. Braff, M. Moosburner, S. J. Yaung, G. M. Church, Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods 10, 1116-1121 (2013) hereby incorporated by reference in its entirety (gRNA 2 and gRNA 3) targeting the same regions. See Fig. 2C. Delivery of TtAgONN-VP64/siDNA into HEK 293 cells demonstrated robust TFAM activation of 20-fold and 60-fold increase in gene expression respectively, comparable to the level achieved by Cas9-VP64/gRNA targeting the same regions (see Fig. 2C). TtAgONN-VP64 provided higher activation than the Cas9ST-VP64 system.
According to one aspect, lower melting temperature (Tm) AT-rich regions of target nucleic acids are targeted by the Ago systems described herein using TtAgONN, which does not have a helicase domain, and therefore increases the likelihood for activation. 14 siDNAs targeting the TFAM promoter as a function of Tm were designed as indicated herein. A reverse correlation of Tm of the targeting sites and TtAgONN-VP64/siDNA activation activities were observed as indicated in Fig. 2D). Because TtAgo lacks a helicase domain, co- transfection of the S. pyogenes Cas9 null mutant (Cas9sp-NN) (see P. Mali, L. Yang, K. M. Esvelt, J. Aach, M. Guell, J. E. DiCarlo, J. E. Norville, G. M. Church, RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013) hereby incorporated by reference in its entirety) improves activation efficiency of the TtAgONN-VP64 system by unwinding the dsDNA substrate. To this end, a siDNA with low activation performance (TFAM-4, Activation -1+0.2 compared to TtAgONN-VP64 alone) was selected and co-transfected with Cas9SPNN/gRNA systems as described in Science 339, 823-826 (2013) targeting between 46
and 187 bp away from the siDNA target site. Binding of Cas9SPNN/gRNA nearby improves activation of TtAgONN-VP64/siDNA, and the optimal efficiency was seen when the two systems are ~128bp apart. See Fig. 3A and 3B. This optimal distance most likely reduces the effects of steric hindrance between the two systems and allows for TtAgONN-VP64 to access its ssDNA target which otherwise is in the dsDNA form. TtAgONN-VP64 activates genes in the human genome, preferably at A-T rich regions, when the ssDNA substrate (target nucleic acid sequence) is more accessible.
As shown in Fig. 3A and 3B, the DNA helicase domain of the null mutant Cas9NN- sp/gRNA systems improves activation of TtAgONN-VP64/siDNA from 1- to 4 -fold when the Cas9 system binds 77 bp - 161 bp upstream of TtAgo binding on the TFAM promoter. Fig. 3A is a schematic of a design of 5 gRNAs to localize Cas9NN-sp at varying distances from TtAgo- VP64/siDNA_TFAM-4. Each gRNA is named 'SPX', where SP denotes the species of Cas9 protein, and X is 1, 2, 3, 4, or 5 to identify the gRNA used. The legend highlights that the gRNA and Cas9NN-sp combine as a unit to localize the system to a specific area in the genome. Similarly, the TtAgo- VP64 and siDNA (TFAM-4) combine as a unit to localize the system to a specific area in the genome. The specific gRNA targeting sequences are described herein. Fig. 3B is data directed to TtAgONN-VP64/siDNA_TFAM-4 activation activities when combining with Cas9NN-sp/gRNA as measured by RT-PCR to amplify a 150 bp region of exon 1 of TFAM. Cas9NN-sp/gRNAs with distance 46bp-187bp to siDNA_TFAM-4 binding site increases the TtAgoNN-VP64/siDNA_TFAM-4 activities 4 fold.
The methods described herein increased mRNA levels using TtAgONN-VP64/siDNA. Methods described herein using TtAgONN-VP64/siDNA also increased protein levels. Fig. 4 depicts immunoblots showing DNA-guided activation of TFAM (25 kDa). Tubulin (50 kDA) served as a control. Intensity of each blot band, /, was calculated using ImageJ software.
Densitometry of TFAM protein was quantified using the equation above. Activators for TFAM (TFAM-1 and TFAM-3 siDNA, respectively) were selected to quantify the amount of TFAM protein in each population after 3 days of transfection. As shown in Fig. 4, a 2.3-fold and 1.9-fold increase of TFAM protein, respectively, was confirmed using the TtAgONN- VP64/TFAM-1 siDNA.
To test the effectiveness of TtAgONN-VP64 activation system across the genome, a panel of endogenous genes (GDF11, ASLC, NANOG, HBG1, IL1B, TERT, SOX2, KLF4, cMYC, and OCT4) was selected and between 3-6 siDNAs were designed targeting AT-rich areas of the respective promoter region (See Fig. 5). Among the ten genes tested, nine genes were successfully activated by a single TtAgONN-VP64/siDNA complex and the activation level showed predicable fashion based on AT content (See Fig. 5). Notably, genes such as TERT and NANOG, that were previously not able to be activated by a single gRNA in the CRISPR/Cas9 system (see A. W. Cheng, H. Wang, H. Yang, L. Shi, Y. Katz, T. W. Theunissen, S. Rangarajan, C. S. Shivalila, D. B. Dadon, R. Jaenisch, Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell research 23, 1163-1171 (2013); P. Perez-Pinera, D. D. Kocak, C. M. Vockley, A. F. Adler, A. M. Kabadi, L. R. Polstein, P. I. Thakore, K. A. Glass, D. G. Ousterout, K. W. Leong, F. Guilak, G. E. Crawford, T. E. Reddy, C. A. Gersbach, RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods 10, 973-976 (2013)) have been robustly activated by a single siDNA in the TtAgONN-VP64/siDNA system. Moreover, TtAgONN-VP64/siDNA activated ASLC, HBG1, SOX2, and OCT4 better than Cas9/gRNA systems. Of note, HBG1-3 siDNA (20% GC, 143 fold activation) significantly outperformed HBG1-2 and HBG1-4 (each 15% GC, 43 and 43 fold activation).
The methods described herein utilize an Ago system to suppress gene expression. Gene suppression activity was demonstrated by interfering with or otherwise blocking the
translational machinery. Three siDNA targeting exon 1 and/or 2 of each gene in the panel described previously (TFAM, NANOG, HBGl, ILIB, TERT, SOX2, KLF4, cMYC, and OCT4) were designed and HEK293 cells were transfected with TtAgONN with siDNA respectively. Notably, 6 out of the 9 constructs tested demonstrated robust gene repression by 10-90% (see Fig. 6). TtAgoNN/siDNAs targeting the exon 1 of HBGl and OCT4 activated gene expression, while TtAgONN/siDNAs targeting exon 2 of HBGl and OCT4 sufficiently repressed gene expression, likely resulting from interaction of TtAgONN with transcription initiation complex.
Fig. 7 is directed to guide DNA sequence specificity. TtAgONN-VP64/siDNA sequence specificity as measured by TFAM activation activities by TtAgONN-VP64/siDNA coupled with different siDNAs was determined. As indicated in Fig. 7, a 5' phosphate on the guide DNA provided TtAgONN-VP64 activities. Mismatches may be allowed under certain circumstances. A mismatch in the middle of the siDNA recognition or spacer sequence showed reduced TtAgONN-VP64/siDNA activity.
Claims
1. A method of altering a eukaryotic cell comprising
providing to the eukaryotic cell a guide DNA sequence complementary to a target nucleic acid sequence,
providing to the eukaryotic cell an Ago enzyme that interacts with the guide DNA sequence and cleaves the target nucleic acid sequence in a site specific manner,
wherein the guide DNA sequence binds to the complementary target nucleic acid sequence and the Ago enzyme cleaves the target nucleic acid sequence in a site specific manner.
2. The method of claim 1 further comprising providing a helicase to the cell where the helicase unwinds a helicase targeting target nucleic acid sequence.
3. The method of claim 1 further comprising providing a helicase to the cell where the helicase unwinds a helicase targeting target nucleic acid sequence where the helicase targeting nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart.
4. The method of claim 1 further comprising providing a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA
colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide RNA targeting target nucleic acid sequence.
5. The method of claim 1 further comprising providing a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide RNA targeting target nucleic acid sequence, and wherein the guide RNA targeting target nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart.
6. The method of claim 1 further including the step of providing a donor sequence and wherein the donor sequence is inserted into the target nucleic acid sequence.
7. The method of claim 1 wherein the eukaryotic cell is a yeast cell, a plant cell or a mammalian cell.
8. The method or claim 1 wherein the eukaryotic cell is a human cell.
9. The method of claim 1 wherein a plurality of guide DNAs are provided into the cell that are complementary to different target nucleic acid sequences and the Ago enzyme cleaves the different target nucleic acid sequences in a site specific manner.
10. A method of altering a eukaryotic cell comprising
providing to the eukaryotic cell a first nucleic acid sequence that is complementary to a target nucleic acid sequence,
providing to the eukaryotic cell a second nucleic acid sequence encoding an Ago enzyme that interacts with the first nucleic acid sequence and cleaves the target nucleic acid sequence in a site specific manner,
wherein the first nucleic acid sequence is a guide DNA,
wherein the second nucleic acid sequence is expressed,
wherein the guide DNA sequence binds to the complementary target nucleic acid sequence and the Ago enzyme that is expressed from the second nucleic acid sequence cleaves the target nucleic acid sequence in a site specific manner.
11. The method of claim 10 further including the step of providing a donor sequence and wherein the donor sequence is inserted into the target nucleic acid sequence.
12. The method of claim 10 wherein the eukaryotic cell is a yeast cell, a plant cell or a mammalian cell.
13. The method or claim 10 wherein the eukaryotic cell is a human cell.
14. The method of claim 10 wherein a plurality of guide DNAs are provided into the cell that are complementary to different target nucleic acid sequences and the Ago enzyme cleaves the different target nucleic acid sequences in a site specific manner.
15. The method of claim 10 wherein the second nucleic acid sequence is present on a recombinant expression vector.
16. A eukaryotic cell comprising
a first nucleic acid sequence that is complementary to a target nucleic acid sequence, a second nucleic acid sequence encoding an Ago enzyme that interacts with the first nucleic acid sequence and cleaves the target nucleic acid sequence in a site specific manner, wherein the first nucleic acid sequence is a guide DNA, and wherein the cell expresses the Ago enzyme, and wherein the guide DNA binds to the complementary target nucleic acid and the Ago enzyme cleaves the target nucleic acid sequence in a site specific manner.
17. The eukaryotic cell of claim 16 wherein the eukaryotic cell is a yeast cell, a plant cell or a mammalian cell.
18. The eukaryotic cell of claim 16 wherein the eukaryotic cell is a human cell.
19. The eukaryotic cell of claim 16 wherein the cell further includes a plurality of nucleic acids encoding a plurality of guide DNA sequences complementary to different target nucleic acid sequences.
20. The eukaryotic cell of claim 16 further comprising a helicase where the helicase unwinds a helicase targeting target nucleic acid sequence.
21. The eukaryotic cell of claim 16 further comprising a helicase where the helicase unwinds a helicase targeting target nucleic acid sequence where the helicase
targeting nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart.
22. The eukaryotic cell of claim 16 further comprising a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide RNA targeting target nucleic acid sequence.
23. The eukaryotic cell of claim 16 further comprising a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide RNA targeting target nucleic acid sequence, and wherein the guide RNA targeting target nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart.
24. The eukaryotic cell of claim 16 further comprising a donor sequence and wherein the donor sequence is inserted into the target nucleic acid sequence.
25. A method of integrating foreign DNA into a nucleic acid sequence of a eukaryotic cell comprising
providing to the cell a guide DNA sequence complementary to a target nucleic acid sequence,
providing to the cell a donor sequence,
providing to the cell an Ago enzyme that interacts with the guide DNA sequence and cleaves the target nucleic acid sequence in a site specific manner,
wherein the guide DNA sequence binds to the complementary target nucleic acid sequence and the Ago enzyme cleaves the target nucleic acid sequence in a site specific manner; and
wherein the donor sequence is integrated into the target nucleic acid sequence.
26. The method of claim 25 further comprising providing a helicase to the cell where the helicase unwinds a helicase targeting target nucleic acid sequence.
27. The method of claim 25 further comprising providing a helicase to the cell where the helicase unwinds a helicase targeting target nucleic acid sequence where the helicase targeting nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart.
28. The method of claim 25 further comprising providing a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide RNA targeting target nucleic acid sequence.
29. The method of claim 25 further comprising providing a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide
RNA targeting target nucleic acid sequence, and wherein the guide RNA targeting target nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart.
30. The method of claim 25 wherein the donor nucleic acid is integrated into the target nucleic acid sequence by homologous recombination.
31. The method of claim 25
wherein the guide DNA is introduced into the cell,
wherein the donor nucleic acid sequence is introduced into the cell,
wherein the Ago enzyme is provided to the cell by introducing into the cell a nucleic acid encoding the Ago enzyme, and
wherein the Ago enzyme is expressed within the cell.
32. The method of claim 25 wherein the cell is a yeast cell, a plant cell or a mammalian cell.
33. The method or claim 25 wherein the cell is a human cell.
34. A method of modulating expression of a target nucleic acid within a eukaryotic cell comprising
providing into the cell a guide DNA complementary to the target nucleic acid sequence,
providing into the cell a nuclease null Ago protein,
wherein the nuclease null Ago protein includes a transcriptional regulator domain connected thereto for modulating target nucleic acid expression in vivo,
wherein the guide DNA and the nuclease null Ago protein including the transcriptional regulator domain co-localize at the target nucleic acid sequence and wherein the transcriptional regulator domain modulates expression of the target nucleic acid sequence.
35. The method of claim 34 further comprising providing a helicase to the cell where the helicase unwinds a helicase targeting target nucleic acid sequence.
36. The method of claim 34 further comprising providing a helicase to the cell where the helicase unwinds a helicase targeting target nucleic acid sequence where the helicase targeting nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart.
37. The method of claim 34 further comprising providing a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide RNA targeting target nucleic acid sequence.
38. The method of claim 34 further comprising providing a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide RNA targeting target nucleic acid sequence, and wherein the guide RNA targeting target
nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart.
39. The method of claim 34 wherein the transcriptional regulator is a transcriptional activator or a transcriptional repressor.
40. The method of claim 34
wherein the guide DNA is introduced into the cell,
wherein the nuclease null Ago protein including the transcriptional regulator domain is provided into the cell by introducing into the cell a nucleic acid encoding the nuclease null Ago protein including the transcriptional regulator domain, and
wherein the cell expresses the nuclease null Ago protein including the transcriptional regulator domain.
41. The method of claim 34 wherein the cell is a eukaryotic cell.
42. The method of claim 34 wherein the cell is a yeast cell, a plant cell or a mammalian cell.
43. The method or claim 34 wherein the cell is a human cell.
44. A method of modulating expression of a target nucleic acid within a eukaryotic cell comprising
providing into the cell a guide DNA complementary to the target nucleic acid sequence, with the guide DNA having a transcriptional regulator domain connected thereto for modulating target nucleic acid expression in vivo,
providing into the cell a nuclease null Ago protein,
wherein the guide DNA and the nuclease null Ago protein co-localize at the target nucleic acid sequence and wherein the transcriptional regulator domain modulates expression of the target nucleic acid sequence.
45. The method of claim 44 further comprising providing a helicase to the cell where the helicase unwinds a helicase targeting target nucleic acid sequence.
46. The method of claim 44 further comprising providing a helicase to the cell where the helicase unwinds a helicase targeting target nucleic acid sequence where the helicase targeting nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart.
47. The method of claim 44 further comprising providing a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide RNA targeting target nucleic acid sequence.
48. The method of claim 44 further comprising providing a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA
colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide RNA targeting target nucleic acid sequence, and wherein the guide RNA targeting target nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart.
49. The method of claim 44
wherein the guide DNA having the transcriptional regulator domain connected thereto is introduced into the cell,
wherein the nuclease null Ago protein is provided into the cell by introducing into the cell a nucleic acid encoding the nuclease null Ago protein, and
wherein the cell expresses the nuclease null Ago protein.
50. The method of claim 44 wherein the cell is a eukaryotic cell.
51. The method of claim 44 wherein the cell is a yeast cell, a plant cell or a mammalian cell.
52. The method or claim 44 wherein the cell is a human cell.
53. A method of modulating expression of a target nucleic acid within a eukaryotic cell comprising
providing into the cell a guide DNA complementary to the target nucleic acid sequence,
providing into the cell a nuclease null Ago protein,
providing into the cell a transcriptional regulator domain for modulating target nucleic acid expression in vivo, wherein the transcriptional regulator domain becomes attached to either the guide DNA or the nuclease null Ago protein,
wherein the guide DNA and the nuclease null Ago protein co-localize at the target nucleic acid sequence and wherein the transcriptional regulator domain modulates expression of the target nucleic acid sequence.
54. The method of claim 53 further comprising providing a helicase to the cell where the helicase unwinds a helicase targeting target nucleic acid sequence.
55. The method of claim 53 further comprising providing a helicase to the cell where the helicase unwinds a helicase targeting target nucleic acid sequence where the helicase targeting nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart.
56. The method of claim 53 further comprising providing a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide RNA targeting target nucleic acid sequence.
57. The method of claim 53 further comprising providing a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide
RNA targeting target nucleic acid sequence, and wherein the guide RNA targeting target nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart.
58. The method of claim 53
wherein the guide DNA is introduced into the cell,
wherein the nuclease null Ago protein is provided to the cell by introducing into the cell a nucleic acid encoding the nuclease null Ago protein,
wherein the transcriptional regulator is provided into the cell by introducing into the cell nucleic acid encoding the transcriptional regulator, and
wherein the cell expresses the nuclease null Ago protein and the transcriptional regulator.
59. The method of claim 53 wherein the cell is a eukaryotic cell.
60. The method of claim 53 wherein the cell is a yeast cell, a plant cell or a mammalian cell.
61. The method or claim 53 wherein the cell is a human cell.
62. A eukaryotic cell comprising
a first nucleic acid sequence that is complementary to a target nucleic acid sequence, a second nucleic acid sequence encoding a nuclease null Ago protein, wherein the nuclease null Ago protein includes a transcriptional regulator domain connected thereto for modulating target nucleic acid expression,
wherein the guide DNA and the nuclease null Ago protein including the transcriptional regulator domain co-localize at the target nucleic acid sequence and wherein the transcriptional regulator domain modulates expression of the target nucleic acid sequence.
63. The eukaryotic cell of claim 62 further comprising a helicase where the helicase unwinds a helicase targeting target nucleic acid sequence.
64. The eukaryotic cell of claim 62 further comprising a helicase where the helicase unwinds a helicase targeting target nucleic acid sequence where the helicase targeting nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart.
65. The eukaryotic cell of claim 62 further comprising a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide RNA targeting target nucleic acid sequence.
66. The eukaryotic cell of claim 62 further comprising a nuclease null Cas9 protein and a guide RNA, wherein the guide RNA is complementary to a guide RNA targeting target nucleic acid sequence, wherein the nuclease null Cas9 and the guide RNA colocalize at the guide RNA targeting target nucleic acid sequence and unwind the guide RNA targeting target nucleic acid sequence, and wherein the guide RNA targeting target nucleic acid sequence and the complementary target nucleic acid sequence are about 75 to 150 base pairs apart.
67. The eukaryotic cell of claim 62 wherein the transcriptional regulator is a transcriptional activator or a transcriptional repressor.
68. The eukaryotic cell of claim 62 further comprising a plurality of guide DNAs that are complementary to different target nucleic acid sequences and the nuclease null Ago protein modulates expression of the different target nucleic acid sequences in a site specific manner.
69. The eukaryotic cell of claim 62 wherein the eukaryotic cell is a yeast cell, a plant cell or a mammalian cell.
70. The eukaryotic cell of claim 62 wherein the eukaryotic cell is a human cell.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/076,022 US20210189388A1 (en) | 2016-02-09 | 2017-02-07 | DNA-Guided Gene Editing and Regulation |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662292962P | 2016-02-09 | 2016-02-09 | |
| US62/292,962 | 2016-02-09 | ||
| US201662396418P | 2016-09-19 | 2016-09-19 | |
| US62/396,418 | 2016-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2017139264A1 true WO2017139264A1 (en) | 2017-08-17 |
Family
ID=59563471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2017/016827 WO2017139264A1 (en) | 2016-02-09 | 2017-02-07 | Dna-guided gene editing and regulation |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US20210189388A1 (en) |
| WO (1) | WO2017139264A1 (en) |
Cited By (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
| US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| WO2019041344A1 (en) * | 2017-09-04 | 2019-03-07 | Hebei University Of Science And Technology | Methods and compositions for single-stranded dna transfection |
| WO2019051278A1 (en) * | 2017-09-07 | 2019-03-14 | The Board Of Trustees Of The Leland Stanford Junior University | Nuclease systems for genetic engineering |
| CN109593694A (en) * | 2018-11-07 | 2019-04-09 | 华中农业大学 | Based on Ngpiwi protein mediated ox source colibacillary gene knock-out bacterial strain and its construction method |
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
| WO2019222036A1 (en) | 2018-05-18 | 2019-11-21 | Insideoutbio, Inc. | Genetically engineered argonaute proteins with enhanced gene silencing activity and methods of use thereof |
| US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
| US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
| US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| US10851370B1 (en) | 2019-07-08 | 2020-12-01 | Pillargo, Inc. | Homologous recombination directed genome editing in eukaryotes |
| US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
| US10912797B2 (en) | 2016-10-18 | 2021-02-09 | Intima Bioscience, Inc. | Tumor infiltrating lymphocytes and methods of therapy |
| EP3812472A1 (en) | 2019-10-21 | 2021-04-28 | Albert-Ludwigs-Universität Freiburg | A truly unbiased in vitro assay to profile off-target activity of one or more target-specific programmable nucleases in cells (abnoba-seq) |
| US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| WO2021130718A1 (en) | 2019-12-24 | 2021-07-01 | Selexis Sa | Targeted integration in mammalian sequences enhancing gene expression |
| US11098325B2 (en) | 2017-06-30 | 2021-08-24 | Intima Bioscience, Inc. | Adeno-associated viral vectors for gene therapy |
| US11147837B2 (en) | 2015-07-31 | 2021-10-19 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| GB202117314D0 (en) | 2021-11-30 | 2022-01-12 | Clarke David John | Cyclic nucleic acid fragmentation |
| US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| US11661590B2 (en) | 2017-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090208534A1 (en) * | 2006-07-26 | 2009-08-20 | The Government Of The United States Of America, As Represented By The Secretary, Dept.Of Health | Attenuated salmonella as a delivery system for sirna-based tumor therapy |
| US20140296503A1 (en) * | 2013-01-01 | 2014-10-02 | A.B. Seeds Ltd. | ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST |
| US20150089681A1 (en) * | 2013-04-11 | 2015-03-26 | Caribou Biosciences, Inc. | Methods of modifying a target nucleic acid with an argonaute |
| US20150110762A1 (en) * | 2013-10-17 | 2015-04-23 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| US20150232881A1 (en) * | 2013-11-07 | 2015-08-20 | Editas Medicine, Inc. | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS |
-
2017
- 2017-02-07 WO PCT/US2017/016827 patent/WO2017139264A1/en active Application Filing
- 2017-02-07 US US16/076,022 patent/US20210189388A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090208534A1 (en) * | 2006-07-26 | 2009-08-20 | The Government Of The United States Of America, As Represented By The Secretary, Dept.Of Health | Attenuated salmonella as a delivery system for sirna-based tumor therapy |
| US20140296503A1 (en) * | 2013-01-01 | 2014-10-02 | A.B. Seeds Ltd. | ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST |
| US20150089681A1 (en) * | 2013-04-11 | 2015-03-26 | Caribou Biosciences, Inc. | Methods of modifying a target nucleic acid with an argonaute |
| US20150110762A1 (en) * | 2013-10-17 | 2015-04-23 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| US20150232881A1 (en) * | 2013-11-07 | 2015-08-20 | Editas Medicine, Inc. | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS |
Non-Patent Citations (1)
| Title |
|---|
| HUTVAGNER , G.: "Small RNA asymmetry in RNAi: Function in RISC assembly and gene regulation", FEBS LETTERS, vol. 579, no. 26, 20 September 2005 (2005-09-20), pages 5850 - 5857, XP027697376 * |
Cited By (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US10954548B2 (en) | 2013-08-09 | 2021-03-23 | President And Fellows Of Harvard College | Nuclease profiling system |
| US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
| US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
| US10912833B2 (en) | 2013-09-06 | 2021-02-09 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
| US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
| US11299755B2 (en) | 2013-09-06 | 2022-04-12 | President And Fellows Of Harvard College | Switchable CAS9 nucleases and uses thereof |
| US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
| US10682410B2 (en) | 2013-09-06 | 2020-06-16 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US11124782B2 (en) | 2013-12-12 | 2021-09-21 | President And Fellows Of Harvard College | Cas variants for gene editing |
| US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US11578343B2 (en) | 2014-07-30 | 2023-02-14 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US11583556B2 (en) | 2015-07-31 | 2023-02-21 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| US11266692B2 (en) | 2015-07-31 | 2022-03-08 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
| US11642375B2 (en) | 2015-07-31 | 2023-05-09 | Intima Bioscience, Inc. | Intracellular genomic transplant and methods of therapy |
| US11642374B2 (en) | 2015-07-31 | 2023-05-09 | Intima Bioscience, Inc. | Intracellular genomic transplant and methods of therapy |
| US11147837B2 (en) | 2015-07-31 | 2021-10-19 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| US10947530B2 (en) | 2016-08-03 | 2021-03-16 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| US11154574B2 (en) | 2016-10-18 | 2021-10-26 | Regents Of The University Of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| US10912797B2 (en) | 2016-10-18 | 2021-02-09 | Intima Bioscience, Inc. | Tumor infiltrating lymphocytes and methods of therapy |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| US11098325B2 (en) | 2017-06-30 | 2021-08-24 | Intima Bioscience, Inc. | Adeno-associated viral vectors for gene therapy |
| US11661590B2 (en) | 2017-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| WO2019041344A1 (en) * | 2017-09-04 | 2019-03-07 | Hebei University Of Science And Technology | Methods and compositions for single-stranded dna transfection |
| CN111836891A (en) * | 2017-09-07 | 2020-10-27 | 莱兰斯坦福初级大学评议会 | Nuclease system for genetic engineering |
| JP2020536502A (en) * | 2017-09-07 | 2020-12-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Nuclease system for genetic manipulation |
| WO2019051278A1 (en) * | 2017-09-07 | 2019-03-14 | The Board Of Trustees Of The Leland Stanford Junior University | Nuclease systems for genetic engineering |
| US11447774B2 (en) | 2017-09-07 | 2022-09-20 | The Board Of Trustees Of The Leland Stanford Junior University | Nuclease systems for genetic engineering |
| WO2019222036A1 (en) | 2018-05-18 | 2019-11-21 | Insideoutbio, Inc. | Genetically engineered argonaute proteins with enhanced gene silencing activity and methods of use thereof |
| CN109593694B (en) * | 2018-11-07 | 2022-04-22 | 华中农业大学 | Ngpiwi protein-mediated bovine-derived escherichia coli gene knockout strain and construction method thereof |
| CN109593694A (en) * | 2018-11-07 | 2019-04-09 | 华中农业大学 | Based on Ngpiwi protein mediated ox source colibacillary gene knock-out bacterial strain and its construction method |
| US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US10851370B1 (en) | 2019-07-08 | 2020-12-01 | Pillargo, Inc. | Homologous recombination directed genome editing in eukaryotes |
| EP3812472A1 (en) | 2019-10-21 | 2021-04-28 | Albert-Ludwigs-Universität Freiburg | A truly unbiased in vitro assay to profile off-target activity of one or more target-specific programmable nucleases in cells (abnoba-seq) |
| WO2021078645A1 (en) | 2019-10-21 | 2021-04-29 | Albert-Ludwigs-Universität Freiburg | A truly unbiased in vitro assay to profile off-target activity of one or more target-specific programmable nucleases in cells (abnoba-seq) |
| WO2021130718A1 (en) | 2019-12-24 | 2021-07-01 | Selexis Sa | Targeted integration in mammalian sequences enhancing gene expression |
| GB202117314D0 (en) | 2021-11-30 | 2022-01-12 | Clarke David John | Cyclic nucleic acid fragmentation |
Also Published As
| Publication number | Publication date |
|---|---|
| US20210189388A1 (en) | 2021-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210189388A1 (en) | DNA-Guided Gene Editing and Regulation | |
| AU2020200163B2 (en) | Orthogonal Cas9 proteins for RNA-guided gene regulation and editing | |
| US20200291370A1 (en) | Mutant Cas Proteins | |
| US10920221B2 (en) | Methods of making and using guide RNA for use with Cas9 systems | |
| US20190161743A1 (en) | Self-Targeting Guide RNAs in CRISPR System | |
| US20180230450A1 (en) | Cas9 Genome Editing and Transcriptional Regulation | |
| AU2019204675A1 (en) | Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing | |
| US20200283758A1 (en) | Methods of Making Guide RNA | |
| US20200377881A1 (en) | Methods of Genome Engineering by Nuclease-Transposase Fusion Proteins | |
| US20210047375A1 (en) | Lentiviral-based vectors and related systems and methods for eukaryotic gene editing | |
| US20190380314A1 (en) | Methods of Genetic Modification of a Cell | |
| WO2019079462A1 (en) | Cas9-based transcription modulation systems | |
| NZ754837B2 (en) | Orthogonal cas9 proteins for rna-guided gene regulation and editing | |
| NZ754836B2 (en) | Orthogonal cas9 proteins for rna-guided gene regulation and editing | |
| NZ716605B2 (en) | Orthogonal cas9 proteins for rna-guided gene regulation and editing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17750630 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17750630 Country of ref document: EP Kind code of ref document: A1 |